MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Bulletin du Cancer' source. Wed, 08 Feb 2012 08:41:17 +0100 http://www.medworm.com/index.php?rid=5659804&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22285357%26dopt%3DAbstract Authors: Médioni J, Guastalla JP, Drouet L Abstract Breast cancer is associated with a low rate of thromboembolic events (TEE) when compared to other cancers, without influence of the histological type on incidence. Risk factors include the stage of cancer, and the patients' profile and management: hospitalization, surgery and presence of a central catheter but also some cytotoxic chemotherapy, tamoxifen, and some anti-angiogenic targeted therapies. The pathophysiology of TEE includes a cross-stimulation phenomenon, involving tumor cells with procoagulant activity, and factors of hemostasis, coagulation and fibrinolysis. Circulating cellular microparticles bearing tissue factor play a major role, as well as thrombogenic platelet interactions with tumor cells via P-selectin. The oc... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5659804 Fri, 27 Jan 2012 05:00:00 +0100 5659804 http://www.medworm.com/index.php?rid=5659803&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22285430%26dopt%3DAbstract Conclusion. CABYR-c is highly expressed in hepatocellular carcinoma tissues and may play an oncogenic role in heptocarcinogenesis as well as its progression. PMID: 22285430 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5659803 Fri, 27 Jan 2012 05:00:00 +0100 5659803 http://www.medworm.com/index.php?rid=5624480&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22265791%26dopt%3DAbstract In this report, we present the results of a constitutionnal and tumoral RB1 analysis in Algerian population. The detection of RB1 gene deletion or mutation was performed by high performance liquid chromatography (HPLC) and sequence analyses in 21 patients. Germline abnormalities were found in 2/21 patients of sporadic unilateral retinoblastoma. The spectrum of germline and tumoral alterations included: three nonsense mutations; one mutation affecting splice site; one deletion and two polymorphisms. In general, for the 21 patients with no family history of the disease, we have identified mutations in germinal level in two of them showing that it is a transmissible form of retinoblastoma in these two cases known to be sporadic. A total of two mutations have not been previously reported. ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5624480 Thu, 19 Jan 2012 05:00:00 +0100 5624480 http://www.medworm.com/index.php?rid=5624479&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22265830%26dopt%3DAbstract Authors: Marcoux I Abstract Patients wish to be fully informed about their health, but some information and its disclosure may pose special challenges depending on the severity of the illness. This prospective observational study investigates the content of information about the disease and treatment, as well as the process by which information is disclosed as part of 51 consultations with people with malignant gliomas. Patients and their relatives were fully informed of the diagnosis and treatments (types, risks, practical details), but disease progression with and without treatment, like the prognosis, was rarely addressed. Relatives were more likely than patients to ask questions related to the severity of the illness and the prognosis, leaving doctors in the difficult position... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5624479 Thu, 19 Jan 2012 05:00:00 +0100 5624479 http://www.medworm.com/index.php?rid=5624478&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22265869%26dopt%3DAbstract Conclusion. The majority of patients chose surveillance. Our short series does not give precise information about their risk of prosthetic failure, a national register should be established. The literature illustrates the low sensitivity of ultrasonography in the diagnosis of intracapsular rupture and the superiority of MRI. In the context of a health alert, could we propose a monitoring tool implant breast MRI in order to minimize the rate of patients carrying a ruptured implant (false negative). PMID: 22265869 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5624478 Thu, 19 Jan 2012 05:00:00 +0100 5624478 http://www.medworm.com/index.php?rid=5624477&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22265907%26dopt%3DAbstract Conclusion. This study outlines the role of mentorship and the lack of practical teaching outside the operating room during the training in surgical oncology in France. PMID: 22265907 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5624477 Thu, 19 Jan 2012 05:00:00 +0100 5624477 http://www.medworm.com/index.php?rid=5624476&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22265942%26dopt%3DAbstract Authors: Noël-Savina E, Descourt R Abstract Granulocyte colony-stimulating factor (G-CSF) are frequently used in oncology and haematology practice. Respiratory disturbance has been reported during administration of G-CSF. G-CSF may induce pulmonary toxicity but this fact remains an open debate because of its frequent association with other drugs. The action of these treatments could explain a part of the pulmonary events but not completely. The specific pulmonary effect of the G-CSF is probably underestimated. Most of these pulmonary events occur in association with other risk factors, mainly when a pneumonia occurs during the neutropenia. However, G-CSF are recommended in febrile neutropenia. PMID: 22265942 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5624476 Thu, 19 Jan 2012 05:00:00 +0100 5624476 http://www.medworm.com/index.php?rid=5624475&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22265994%26dopt%3DAbstract Authors: Laval G, Rousselot H, Toussaint-Martel S, Mayer F, Terrebonne E, François E, Brixi H, Nguyen T, Bourdeix I, Bisot-Locard S, Zelek L Abstract This phase II, multicenter, randomized, double-blind, non-comparative study assessed the efficacy and safety of immediate-release octreotide and octreotide LAR, in combination with corticosteroids and standard medical care, on the symptoms of inoperable malignant bowel obstruction (MBO) due to peritoneal carcinomatosis. The primary efficacy endpoint was "success" at day 14 defined as a composite endpoint including the absence of a nasogastric tube, and vomiting less than twice per day and no use of anticholinergic agents. Patients in the octreotide arm received octreotide LAR 30 mg intramuscular (im) on days 1, 29 and 57, as w... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5624475 Thu, 19 Jan 2012 05:00:00 +0100 5624475 http://www.medworm.com/index.php?rid=5624474&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22266042%26dopt%3DAbstract Conclusions. Systematic retroperitoneal lymphadenectomy has a potentially therapeutic role on survival in surgically staged patients with endometrial cancer. PMID: 22266042 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5624474 Thu, 19 Jan 2012 05:00:00 +0100 5624474 http://www.medworm.com/index.php?rid=5624473&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22266074%26dopt%3DAbstract Authors: Brugières L, Branchereau S, Laithier V Abstract Tumours and pseudotumours of the liver are a heterogeneous group of neoplasm including 60% of malignant tumours. Malignant liver tumours account for less than 2% of the lesions in children and vary considerably in incidence throughout the paediatric age range, with hepatoblastoma, rhabdoid tumour of the liver, hemangioendothelioma, biliary tract rhabdomysosarcoma and mesenchymal hamartoma in the first two years of life and hepatocellular carcinoma, focal nodular hyperplasia, and undifferentiated sarcoma in older children and adolescents. Treatment of malignant epithelial tumours is based on the surgical resection of the tumour associated with pre- and postoperative chemotherapy including cisplatinum. Modalities of the treatm... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5624473 Thu, 19 Jan 2012 05:00:00 +0100 5624473 http://www.medworm.com/index.php?rid=5624472&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22266799%26dopt%3DAbstract This study is based on a retrospective database of 1375 patients who underwent sentinel node (SN) biopsy for breast cancer. In case of micrometastase or ITC in SN with completion axillary dissection, we examined if non-sentinel lymph node status has changed the indications of adjuvant treatments (chimiotherapy or radiotherapy). The results of our study show that non-sentinel lymph node status modify systemic therapy for a very few patients (less than 4% concerning chimiotherapy and less than 15% concerning radiotherapy). PMID: 22266799 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5624472 Thu, 19 Jan 2012 05:00:00 +0100 5624472 http://www.medworm.com/index.php?rid=5624482&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22257744%26dopt%3DAbstract Authors: Vauleon E, Mesbah H, Gedouin D, Lecouillard I, Louvel G, Hamlat A, Riffaud L, Carsin B, Quillien V, Audrain O, Lesimple T Abstract Despite progress in the initial management of glioblastoma (GB), the vast majority of patients will experience recurrence within 2-3 years. The medical treatment of these recurrences is being modified by the use of antiangiogenic therapies. Twenty-four patients, who relapsed from GB after chemoradiation followed by adjuvant temozolomide in Rennes, were treated by conventional chemotherapy (nitrosourea) or by the combination of irinotecan and bevacizumab. In this retrospective analysis, overall survival from diagnosis of recurrence was significantly longer in patients treated with the combination of bevacizumab and irinotecan than with nitrosour... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5624482 Tue, 17 Jan 2012 05:00:00 +0100 5624482 http://www.medworm.com/index.php?rid=5624481&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22257781%26dopt%3DAbstract Conclusions. Our result suggests that first-line endocrine therapy is a viable therapeutic option for a selected population of metastatic breast cancer patients with HER2-positive tumors. Genomic and transcriptomic signature could help to identify tumors that remain dependant of estrogen-signaling pathway. PMID: 22257781 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5624481 Tue, 17 Jan 2012 05:00:00 +0100 5624481 http://www.medworm.com/index.php?rid=5603973&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22236833%26dopt%3DAbstract Authors: Lheureux S, Joly F Abstract Endometrial cancer is the most common gynaecological cancer in western countries. Radiotherapy remains the mainstay of postoperative management, but accumulating data show that adjuvant chemotherapy may display promising results after surgery. Characteristic features of the patients and disease, type of treatment including modality of surgery, radiation and chemotherapy are different from studies reported. The results from these trials are inconsistent but certain groups of patients with high-risk features could have advantage to adjuvant chemotherapy. The indication of adjuvant chemotherapy must be discussed in this situation taking into account the patient's profile with potential comorbidities and risk of toxicities. PMID: 22236833 [PubMe... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5603973 Tue, 10 Jan 2012 05:00:00 +0100 5603973 http://www.medworm.com/index.php?rid=5603972&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22236886%26dopt%3DAbstract Authors: Tazi Y, Pautier P, Lhommé C Abstract Endometrial cancer has generally a good prognosis when it is diagnosed at an early stage but remains incurable at an advanced stage (recurrent or metastatic) with only few therapeutic options. Hormone therapy is the treatment of choice in case of slowly progressive disease with a tumor expressing hormonal receptors due to its favorable safety profile. Taxanes, anthracyclines and platinum compounds are the most active chemotherapy agents with greater response rates when they are combined at the price of a significant toxicity. Targeted therapies based on a better understanding of tumor biology are being evaluated with some promising results. PMID: 22236886 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5603972 Tue, 10 Jan 2012 05:00:00 +0100 5603972 http://www.medworm.com/index.php?rid=5578823&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22231748%26dopt%3DAbstract Authors: Mazeron R, Khodari W, Gilmore J, Champoudry J, Dumas I, Morice P, Lhommé C, Haie-Méder C Abstract Several randomized studies published in recent years have greatly changed the management of postoperative endometrial cancer, especially for lesions of intermediate prognosis. Vaginal brachytherapy is now standard treatment for these lesions at the expense of external beam radiation, which, despite an improvement in locoregional control, has no impact on overall survival. This review aims to take stock of new indications for vaginal brachytherapy detailing the trials that led to change standards or care. PMID: 22231748 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5578823 Mon, 09 Jan 2012 05:00:00 +0100 5578823 http://www.medworm.com/index.php?rid=5578822&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22231875%26dopt%3DAbstract This article describes anatomopathological and molecular features of this disease. Type I carcinoma, the most frequent, develops in a context of hyperoestrogenia. Endometrial glandular hyperplasia is the precursor lesion. The histological type is an endometrioid carcinoma. Its prognosis is good. Type II carcinoma is less frequent. It occurs on an atrophic mucosa. It is usually a more aggressive tumor like serous adenocarcinoma, clear cells carcinoma or carcinosarcoma with a poor prognosis. Type I and type II carcinoma also present different molecular pathways. PTEN inactivation, an early event in carcinogenesis, is the most frequent abnormality in type I carcinoma. An average of 28% of type I carcinoma also acquire PI3K mutations. On the contrary, P53 mutation is involved in 90% of type II... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5578822 Mon, 09 Jan 2012 05:00:00 +0100 5578822 http://www.medworm.com/index.php?rid=5561589&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22212613%26dopt%3DAbstract Authors: Fumagalli I, Leblanc E, Nickers P Abstract Endometrial cancer is a common malignancy. Management of these tumors depends on several risk factors such as FIGO staging, myometrial invasion, histology or pelvic lymph node involvement. According to those factors, low risk, intermediate and high risk groups were defined. A high risk endometrial cancer has a poorer prognostic and more risks of recurrence. Treatment of such disease should be more agressive. However modalities of these treatments have not yet been clearly defined. PMID: 22212613 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5561589 Tue, 03 Jan 2012 05:00:00 +0100 5561589 http://www.medworm.com/index.php?rid=5561588&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22212645%26dopt%3DAbstract Authors: Koskas M, Yazbeck C, Walker F, Delorme P, Azria E, Luton D, Madelenat P Abstract In endometrial carcinoma (EC) and atypical hyperplasia (AH) diagnosed in childbearing years, the principle of uterine sparing consists in prescription of antigonadotropic treatment to obtain the remission of the endometrial lesion and allow pregnancy, always with a close follow-up looking for progression or persistence of the tumour. Studies evaluating this strategy have suggested the safety of such an approach, but numerous questions remain unanswered, like those concerning the type and the duration of treatment, and the systematic use of Assisted Reproductive Technologies… We performed a critical literature review in order to analyse patients and tumoral characteristics, treatment manageme... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5561588 Tue, 03 Jan 2012 05:00:00 +0100 5561588 http://www.medworm.com/index.php?rid=5550768&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22198299%26dopt%3DAbstract Authors: Daraï E, Zacharopoulou C, Touboul C, Chéreau E, Ballester M Abstract Based on two randomized trials and a meta-analysis, the recommendations of the National Cancer Institute (INCa) have validated the absence of systematic pelvic lymphadenectomy for patients with endometrial cancer at low risk (type 1 histology stage IA grade 1-2) and intermediate (type 1 histology stage IA grade 3 and IB grade 1-2) but without taking into account the contribution of the sentinel node (SN) procedure. The senti-endo trial assessing the role of the SN procedure in patients with early stages endometrial cancer showed that the detection rate by hemi-pelvis right and left were 77 and 76%, respectively. The detection rate per patient was 89%. Among patients with at least a SN detected, the dete... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5550768 Mon, 26 Dec 2011 05:00:00 +0100 5550768 http://www.medworm.com/index.php?rid=5550767&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22198346%26dopt%3DAbstract Authors: Guyon F, Stoeckle E, Thomas L, Petit A, Sire M, Floquet A Abstract Endometrial cancers with peritoneal spread are stage IVB of FIGO classification. Their pattern is similar to that of ovarian cancer. Optimal debulking surgery and chemotherapy are predictor of better overall and disease free survival. Despite the poor outcome, there is a need for new treatment options. Recommended management for this group of patients should consist of surgical cytoreduction followed by chemotherapy. There may be a role for neoadjuvant chemotherapy followed by interval surgery in selected subgroups of patients. PMID: 22198346 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5550767 Mon, 26 Dec 2011 05:00:00 +0100 5550767 http://www.medworm.com/index.php?rid=5550766&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22198406%26dopt%3DAbstract Authors: Poilblanc M, Samouelian V, Querleu D Abstract Endometrial cancer staging is based on surgery. No matter the age of the patient, the surgical staging includes at least a total hysterectomy with bilateral salpingo-oophorectomy. Twenty to 25% of the patients diagnosed with endometrial cancer are younger than 45 years. Although some discrepancies among series may be observed, in this population, endometrial cancers are mainly of lower grade, confined to the uterus (without ovarian involvement) and of better prognosis compared to older patients. The impact of premature menopause on the quality of life, cardiovascular and bone systems should not be neglected. This raises the issue of the systematic bilateral oophorectomy legitimacy while staging endometrial cancer staging in y... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5550766 Mon, 26 Dec 2011 05:00:00 +0100 5550766 http://www.medworm.com/index.php?rid=5550765&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22198465%26dopt%3DAbstract Authors: Caron O Abstract As nearly 5% of all endometrial cancers occur because of a predisposition, this possibility has systematically to be explored. The hallmarks of predisposition, a young age at diagnosis, a personal or a familial history of cancer, have to be searched systematically. The identification of a predisposition in a family has a major impact on the management of the proband or his relatives. The endometrial cancer main predisposition is Lynch's syndrome. In this review, we will focus on this condition and describe its clinical manifestations, the underlying molecular mechanisms, the cancer risks and the management guidelines. We will also get onto some far less frequent other predispositions. PMID: 22198465 [PubMed - as supplied by publisher] (Source: Bulletin... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5550765 Mon, 26 Dec 2011 05:00:00 +0100 5550765 http://www.medworm.com/index.php?rid=5550770&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22192868%26dopt%3DAbstract Authors: Narducci F, Jean-Laurent M, Lambaudie E, Coutty N, Leblanc E Abstract The recommendations of the Institut national du cancer and of the Société francaise d'oncologie gynécologique in endometrial carcinoma (2010) reported that laparoscopy is the standard surgical approach for patients with apparent stage FIGO I in preoperative outcomes including MRI (www.e-cancer.fr). For patients with stage FIGO greater than I, laparotomy is the standard surgical approach. In case of lymph nodes or peritoneal restaging, the laparoscopy could be a good option especially by extraperitoneal route in patients with recent first surgery. PMID: 22192868 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5550770 Tue, 20 Dec 2011 05:00:00 +0100 5550770 http://www.medworm.com/index.php?rid=5550769&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22194273%26dopt%3DAbstract Authors: de Lagausie P, Sarnacki S, Orbach D, Petit P, Joubert C Abstract The pseudopapillary tumor of the pancreas (or Frantz's tumor) is a rare exocrine pancreatic tumor with a low degree of malignancy. It occurs more frequently among women between 20 and 40 years of age and in the Asian population. This tumor is rarer in the pediatric population. The symptoms are subtle, the most striking being pain and an abdominal mass. Pathologically, the tumor is usually well circumscribed with regions of necrosis, hemorrhage and cystic degeneration. A thick, fibrous capsule is often present. The low grade of malignancy of this tumor with a fibrous capsule led to perform a surgical resection. The localization and local invasion determine the surgical technique. Despite its potential for loc... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5550769 Tue, 20 Dec 2011 05:00:00 +0100 5550769 http://www.medworm.com/index.php?rid=5536666&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22182714%26dopt%3DAbstract This article proposed by the editorial board of the Bulletin du Cancer proposes to discuss new information with a drop of a few months with the aim of trying to identify the results that can have an immediate or future impact on clinical practice. PMID: 22182714 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536666 Fri, 16 Dec 2011 05:00:00 +0100 5536666 http://www.medworm.com/index.php?rid=5536665&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22182739%26dopt%3DAbstract This article is an update of the literature data to enable everyone to form an opinion on the subject. Future prospects are considered. PMID: 22182739 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536665 Fri, 16 Dec 2011 05:00:00 +0100 5536665 http://www.medworm.com/index.php?rid=5536664&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22182766%26dopt%3DAbstract Authors: Uzan C, Gouy S, Pautier P, Lhommé C, Duvillard P, Haie-Meder C, Morice P Abstract Most of patients with endometrial cancer are diagnosed at an early stage and therapeutics should be more limited in order to decrease morbidity. New French recommendations have been published in 2010, integrating this objective of therapeutic de-escalation. This review presents the take home messages of these recommendations (pretherapeutic staging, new FIGO staging and its criticism, evolution of surgical treatment more limited for low risk patients, management of specific histology, postoperative treatment, follow up) and the possible difficulties in the daily use of these recommendations. Indeed, the current recommended management for endometrial cancer is more complex but the ultimate go... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536664 Fri, 16 Dec 2011 05:00:00 +0100 5536664 http://www.medworm.com/index.php?rid=5536668&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22172776%26dopt%3DAbstract Authors: Massard C, Auger N, Lacroix L, Bénard J Abstract In the last decades, rarity of chromosomal rearrangements and fusion genes detected in epithelial cancers in using classical karyotyping led to consider these genomic events as specifically restricted to haematological neoplasia and mesenchymal tumors. Today, gene positioning as well as bio-informatics approaches has enabled identifying in carcinoma various fusion genes subsequent to chromosomal translocations, inversions, or deletions. Thus, gene fusion formation appears as a common mechanism in oncology that concerns most of human cancers, independent of original tissue lineage. At a clinical point of view, applications of fusion genes in terms of diagnosis, prognosis and therapeutics can be envisioned. This review will p... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536668 Thu, 15 Dec 2011 05:00:00 +0100 5536668 http://www.medworm.com/index.php?rid=5536667&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22172939%26dopt%3DAbstract Authors: Tuech JJ, Bridoux V, Schwarz L, Oden-Gangloff A, Michel P, Michot F Abstract One of the objectives of the French strategic plan for cancer 2009-2013 is to structure the need for referral surgery, particularly for low rectal carcinoma. However, low rectal cancer is not the only situation in the field of rectal surgery where expert unit are needed for the referral of appropriate patients. We developed the multidisciplinary strategies for low rectal cancer, advanced rectal cancer, recurrent rectal cancer and peritoneal carcinomatosis. Optimal management of these difficult situations can give a chance of long term survival while a non-optimal management could jeopardise the future of patients by changing a potentially curable disease into an incurable one. PMID: 22172939 [... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536667 Thu, 15 Dec 2011 05:00:00 +0100 5536667 http://www.medworm.com/index.php?rid=5536672&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22157576%26dopt%3DAbstract Authors: Renard-Penna R, Marcy PY, Lacout A, Thariat J Abstract Imaging of the kidney relies on three main imaging modalities: ultrasound, CT scan and MRI, on one hand, and scintigraphy, on the other hand. First intent ultrasound provides anatomic/vascular and functional information. Tissue perfusion assessment using ultrasound can be improved using contrast agents. Renal ultrasound is particularly useful but remains operator and tumor/patient-dependent (obese, ectopic kidney, type and site of tumor). It is cheap and does not irradiate. Ultrasound contrast agents can improve the sensitivity of ultrasound in many clinical situations. Intravenous urography has been replaced by CT scan. Multi-slice CT scan is indeed the main renal imaging modality: it allows for angiographic and uro... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536672 Mon, 12 Dec 2011 05:00:00 +0100 5536672 http://www.medworm.com/index.php?rid=5536673&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22157516%26dopt%3DAbstract Authors: Gueutin V, Deray G, Isnard-Bagnis C Abstract The kidneys are responsible for the urinary excretion of uremic toxins and the regulation of several body systems such as intra and extracellular volume status, acid-base status, calcium and phosphate metabolism or erythropoiesis. They adapt quantitative and qualitative composition of the urine to keep these systems in balance. The flow of plasma is filtered in the range of 120 mL/min, and depends on the systemic and renal hemodynamics which is subject to self-regulation. The original urine will then be modified in successive segments of the nephron. The proximal nephron is to lead the massive reabsorption of water and essential elements such as sodium, bicarbonates, amino-acids and glucose. The distal nephron includes the dis... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536673 Fri, 09 Dec 2011 05:00:00 +0100 5536673 http://www.medworm.com/index.php?rid=5536671&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22157594%26dopt%3DAbstract Authors: Lacombe J, Solassol J, Pouget JP, Coelho M, Azria D Abstract Radiotherapy allows locoregional control with systemic impact in some indications. Technologic advances decrease the dose received by normal tissues leading to a low crude number of late side effects near to 5%. Intrinsic radiosensitivity are still of interest in this context of high level of technology and optimized treatments. Assays of radiosensitivity are detailed in this article arguing the negative results but also the perspectives. PMID: 22157594 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536671 Fri, 09 Dec 2011 05:00:00 +0100 5536671 http://www.medworm.com/index.php?rid=5536670&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22157636%26dopt%3DAbstract Authors: Mouttet-Audouard R, Gras L, Comet B, Lartigau E Abstract Recurrences or second primary head and neck cancers meant, for a long time, therapeutic dead ends. Surgery was the standard treatment, but could only be achieved in 25% of the patients. The GETTEC-GORTEC (99-01) randomized trial showed that radiochemotherapy improved disease-free survival for a highly selected population. For inoperable patients, three options can be discussed: supportive care only, chemotherapy or radiotherapy with or without chemotherapy. The EXTREME protocol showed that combining platinum, 5FU and cetuximab improved overall survival for recurrent or metastatic forms. This is certainly the best option for advanced forms, which are not accessible to radiotherapy. Concerning radiotherapy, only one r... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536670 Fri, 09 Dec 2011 05:00:00 +0100 5536670 http://www.medworm.com/index.php?rid=5536669&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22157699%26dopt%3DAbstract Authors: Ravinet A, Gay Belille M, Lemal R, Veronese L, Bay JO, Prie N Abstract Oncogenesis is correlated with the occurrence of multiple genomic events allowing cancer cells to acquire new properties, including the capacity of survival and proliferation with down regulated control signals. Among those genomic events, the study of recurrent translocations, particularly common in oncohematology, has allowed for a better understanding of leucemogenesis and lymphomagenesis mechanisms. These translocations are classically distinguished depending on their physiopathologic consequences. It may encode for a fusion gene leading to a chimeric protein, which exhibits a new activity or an aberrant one, corresponding in most cases to the constitutive activation of a proto-oncogene. In other ca... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536669 Fri, 09 Dec 2011 05:00:00 +0100 5536669 http://www.medworm.com/index.php?rid=5536680&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22146100%26dopt%3DAbstract This article provides recommendations for the use of drugs used for pain treatment after pointing out: 1) etiological and pathophysiological elements of pain; 2) therapeutic strategies for pain management; 3) data regarding renal failure in cancer and; 4) a point on drugs pharmacokinetics. PMID: 22146100 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536680 Mon, 05 Dec 2011 05:00:00 +0100 5536680 http://www.medworm.com/index.php?rid=5536679&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22146132%26dopt%3DAbstract Authors: Thariat J, Janus N, Barrière J, Launay-Vacher V Abstract The use of targeted therapies is increasing in the treatment of cancer. Monoclonal antibodies and tyrosine kinase inhibitors are the most commonly used but other classes such as mTOR inhibitors are increasingly prescribed. These treatments are often given in the long term in metastatic and maintenance treatments. It is therefore important to monitor the occurrence of immediate toxicities but also later and cumulative toxicities. Renal toxicities of targeted therapies are most often due to structural damages of the nephron. The anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor (VEGFR) have renal side effects since growth factor receptors are expressed in the kidney. The... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536679 Mon, 05 Dec 2011 05:00:00 +0100 5536679 http://www.medworm.com/index.php?rid=5536678&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22146223%26dopt%3DAbstract Authors: Thariat J, Vendrely B, Roca S, Ravaud A, Bay JO, Lacout A, Marcy PY, Thyss A, Besancenot JF Abstract Renal alterations in the context of neoplastic disease are relatively frequent manifestations but are overall poorly reported. A search in the English and French literature was performed using the following key words: "cancer", "renal", "paraneoplastic syndrome", "glomerulopathy" and "kidney failure". The various renal manifestations can be divided into specific and paraneoplastic. They include paraneoplastic glomerulopathies (membranous glomerulonephristis being the most frequent), direct involvement of the renal parenchyma, hydroelectrolytic abnormalities (hypercalcemia, inappropriate antidiuretic hormone secretion…), retroperitoneal fibrosis, micro-angiothrombotic dise... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536678 Mon, 05 Dec 2011 05:00:00 +0100 5536678 http://www.medworm.com/index.php?rid=5536677&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22146261%26dopt%3DAbstract Authors: Benbrahim Z, Massard C, El Mesbahi O Abstract Angiogenesis is crucial for the growth and metastasis of many cancers. A series of new inhibitors of angiogenesis are now in intensive development. Recent preclinical studies suggest that frequent administration of certain conventional cytotoxic agents at low doses increases their putative antiangiogenic activity. Moreover, many clinical trials confirm efficacy of this metronomic chemotherapy in terms of clinical benefice and survival prolongation. Combining metronomic chemotherapy with hormonotherapy, angiogenesis inhibitors and radiotherapy increases efficacy. Many biomarkers are used to predict optimal drugs and appropriate use of them. This review describes experimental and clinical studies published and discuss its potenti... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536677 Mon, 05 Dec 2011 05:00:00 +0100 5536677 http://www.medworm.com/index.php?rid=5536676&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22146312%26dopt%3DAbstract Authors: Fayard F, Guérin S, Hill C Abstract Cancer is a rare pathology before the age of 40: a total of 14,000 new cases have been diagnosed in patients under age 40 in 2005, 1,700 under age 15 and 12,500 in the age-group of 15 to 39, this represents 4% of the cancers diagnosed in 2005. The number of deaths is small: in 2008, 2,235 patients died before age 40 in France, 246 under age 15 and 1,989 between age 15 and 39; this corresponds to 1% of the cancer deaths in 2008. The incidence increased between 1980 and 2005, both in the population aged 0 to 14 and in the population aged 15 to 39. Overall, cancer mortality has been decreasing for more than 25 years. The only increase in mortality is observed for brain tumours in children. The overall incidence increase is mostly due to... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536676 Mon, 05 Dec 2011 05:00:00 +0100 5536676 http://www.medworm.com/index.php?rid=5536675&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22146366%26dopt%3DAbstract Authors: Solassol J, Harmand PO, Maudelonde T, Pujol JL Abstract Because of its development marked by a long preclinical phase and the difficulties to screen patients, lung cancer is usually diagnosed at an advanced stage of disease, even in high-risk populations. The advent of new molecular tools, including proteomics, has promoted the study of the humoral response to cancer and has allowed the demonstration of the appearance of a large number of autoantibodies against tumor antigens in the serum of patients. In this article, we describe the different molecular approaches used to identify autoantibodies and immunogenic proteins and we present the different clinical studies applied to early detection of lung cancer. Early trials demonstrated the development of a humoral response se... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536675 Mon, 05 Dec 2011 05:00:00 +0100 5536675 http://www.medworm.com/index.php?rid=5536674&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22146408%26dopt%3DAbstract In conclusion, our findings suggest that leukemogenesis is associated with carcinogen metabolism and consequently related to environmental exposures. PMID: 22146408 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5536674 Mon, 05 Dec 2011 05:00:00 +0100 5536674 http://www.medworm.com/index.php?rid=5475818&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22133889%26dopt%3DAbstract Authors: Launay-Vacher V, Zimner-Rapuch S, Moranne O Abstract The evaluation of renal function in patients with cancer is necessary. Measuring the actual glomerular filtration rate of the patient is the gold standard. This is usually done using a measure of the renal clearance of a marker of glomerular filtration rate (inulin) or a radio-marker (EDTA Chrome 51, (51)Cr-EDTA). However, these measures are complex and very constraining for the patient and in terms of organization and equipment. It is possible to estimate renal function by calculation. There are in the literature many evaluation formulae available. However, it is essential to use a tool reliable enough to determine an appropriate estimate of renal function, and adjust the doses of treatment if necessary. The choice of t... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5475818 Thu, 01 Dec 2011 05:00:00 +0100 5475818 http://www.medworm.com/index.php?rid=5475821&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22133711%26dopt%3DAbstract Authors: Gligorov J, Launay-Vacher V, Aapro M Abstract Intravenous bisphosphonates are one of the treatments of choice of bone metastases in cancer patients. Their efficacy on the frequency and the number of skeletal events has been clearly shown. They also exhibit some variable activity on metastatic bone pain. Most often, the side effects of IV bisphosphonates are well-tolerated. However, new and more severe side effects have also been reported, with an increasing incidence. Those toxicities apply to the bone (osteonecrosis of the jaw) and the kidneys (acute renal failure) are not a class-effect of bisphosphonates and prevention of those effects is mandatory. Recent data on denosumab do not allow any recommendation for a potential "light" renal monitoring in patients treated with... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5475821 Wed, 30 Nov 2011 05:00:00 +0100 5475821 http://www.medworm.com/index.php?rid=5475820&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22133734%26dopt%3DAbstract Authors: Janus N, Launay-Vacher V, Deray G, Thyss A, Thariat J Abstract The increased incidence of cancer in dialysis patients has been discussed since the mid-70s. Consequently, oncologists, nephrologists and pharmacists are increasingly facing challenging situations of cytotoxic drug handling in dialysis patients. In dialysis patients, two main issues must be considered. First, renal function of hemodialysis (HD) patients is no longer functional. Therefore, these patients may necessitate drug dosage reduction, namely drug prescription, must be cautiously checked before administration with appropriate dosage adjustment whenever necessary to ensure efficacy while avoiding overdosage and related side effects. Secondly, drug clearance by dialysis must be taken into account for approp... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5475820 Wed, 30 Nov 2011 05:00:00 +0100 5475820 http://www.medworm.com/index.php?rid=5475819&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22133789%26dopt%3DAbstract Authors: Janus N, Launay-Vacher V, Deray G, Islam MS, Thyss A, Thariat J Abstract The increased incidence of cancer in dialysis patients has been discussed since the mid 1970s. Furthermore, the emergence of targeted therapies (TT) requires oncologists, nephrologists and pharmacists to question themselves about the handling of these new classes of drugs in dialysis patients. While the cytotoxic drugs have been used in oncology for a long time, these new molecules are recent and clinical studies on their management in dialysis patients are missing. We reviewed the international literature on the pharmacokinetics, efficacy, tolerance and dosage adjustment of TT used in hemodialysis cancer patients, using the following keywords: kidney; renal; dialysis; hemodialysis; end-stage renal di... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5475819 Wed, 30 Nov 2011 05:00:00 +0100 5475819 http://www.medworm.com/index.php?rid=5475817&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22133915%26dopt%3DAbstract Authors: Conroy T, Mitry E Abstract The outcome for patients with metastatic pancreatic ductal adenocarcinoma is dismal. In this article, we will review current first-line treatments for metastatic pancreatic adenocarcinoma focusing on phase III randomized studies. Single-agent gemcitabine, the reference treatment since 1995, offers only slight benefit. Numerous trials using gemcitabine in combination with different cytotoxic agents have resulted in no major improvement compared to gemcitabine alone. Only the gemcitabine-erlotinib combination has shown a small, but statistically improvement in survival. In selected patients with good performance status ECOG 0-1, no cardiac ischemia and almost normal bilirubin level, the Folfirinox regimen, when compared to gemcitabine as single age... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5475817 Wed, 30 Nov 2011 05:00:00 +0100 5475817 http://www.medworm.com/index.php?rid=5475816&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22133994%26dopt%3DAbstract Authors: Heudel PE, Tredan O, Ray-Coquard I, Treilleux I, Guastalla JP, Bachelot T Abstract Hormonal dependence of breast cancer has been known for a long time, yet about half of breast cancers with estrogen receptor will not respond to antihormonal therapy. Now, we know that this resistance may be related to a dysfunction of the estrogen pathway, or that of growth factors and particularly the pathway of cell activation PI3K/Akt/mTOR. Prevention of these different mechanisms of resistance could involve combination therapies such as anti-estrogens (SERMs, aromatase inhibitors) with inhibitors of the activity of growth factors that are particularly temsirolimus and everolimus for the activation pathway cell PI3K/Akt/mTOR. PMID: 22133994 [PubMed - as supplied by publisher] (Source... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5475816 Wed, 30 Nov 2011 05:00:00 +0100 5475816 http://www.medworm.com/index.php?rid=5475815&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22134048%26dopt%3DAbstract Authors: Taïeb S, Rocourt N, Narducci F, Ceugnart L Abstract Endometrial cancer is staged according to the International Federation of Gynecology and Obstetrics surgical system. Clinical estimation of stage, however, can be inaccurate in more than 20%, and therefore, preoperative imaging of the disease may assist in planning the optimal course of treatment. Magnetic resonance imaging (MRI) may detect gross myometrial extension or extension of tumor to the cervical stroma, which can alter management and therefore help in preoperative surgical planning. This issue is increasingly relevant as less invasive surgical techniques, such as laparoscopic surgeries, are becoming more commonplace for lower stage cancers. Currently, MRI is the most widely used modality for preoperative plannin... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5475815 Wed, 30 Nov 2011 05:00:00 +0100 5475815 http://www.medworm.com/index.php?rid=5475814&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22134056%26dopt%3DAbstract Authors: Gonçalves A, Viens P, Gilabert M, Turrini O, Lambaudie E, Prebet T, Farnault B, Eisinger F, Gorincour G, Bertucci F Abstract The expected increase in cancer incidence emphasizes the need for specific training in this area, including either family physician or specialized oncologists. In France, the fourth to sixth years of medical teaching include both theoretical classes at the university and daily actual practice at the hospital. Thus, clinical rotations are thought to play a major role in the training of medical students and also largely participate to the choice of the student of his/her final specialty. Pedagogic quality of these rotations is dependent on multiple parameters, including a rigorous planification of the expected learning. Here, we reported a systemic pl... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5475814 Wed, 30 Nov 2011 05:00:00 +0100 5475814 http://www.medworm.com/index.php?rid=5457010&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22123599%26dopt%3DAbstract Authors: Zimmer-Rapuch S, Lheureux S, Brocard F, Janus N, Launay-Vacher V, Ray-Coquard I Abstract Anticancer drug management is complicated especially in renal insufficiency patients, a frequent situation in oncology. Several aspects need to be taken into account: first, the dosage. In this population, the kidney fails to eliminate drugs. Consequently, dosage adjustment can be necessary for drugs with pharmacokinetic profile altered by renal insufficiency in order to avoid dose-related side effects due to accumulation of the drug. Secondly, renal tolerance is an important aspect of anticancer drug management as renal insufficiency is a risk factor for developing renal side effects. Prevention of renal side effects is essential and means to limit this toxicity should be used, especi... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5457010 Fri, 25 Nov 2011 05:00:00 +0100 5457010 http://www.medworm.com/index.php?rid=5457011&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22106161%26dopt%3DAbstract Authors: Beuzeboc P, Le Tourneau C, Gligorov J, Janus N, Spano JP, Ray-Coquard I, Deray G, Launay-Vacher V Abstract The Renal Insufficiency and Anticancer Medications (IRMA) study is a French national, observational study, which demonstrated the high prevalence of abnormal renal function in a population of 4,684 solid tumour patients, treated in 15 cancer centers. Among them, 7.2% had a SCR level ≥ 110 mmol/L. In the 1 898 patients with breast cancer, only 31 patients (1.63%) had a SCR level ≥ 110 mmol/L. Nevertheless, respectively 51.8 and 50.8% had a creatinine clearance estimated with the Cockcroft-Gault and aMDRD formulae, below 90 mL/min. Even if the most used medications (anthracyclins, taxanes, trastuzumab, hormone therapies) are not nephrotoxic, these re... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5457011 Tue, 22 Nov 2011 05:00:00 +0100 5457011 http://www.medworm.com/index.php?rid=5422967&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22088807%26dopt%3DAbstract Authors: Bouillet T, Ali AM, Thariat J Abstract The kidneys are dose-limiting organs when total body irradiation or irradiation of the digestive tract is planned. The incidence of radiation-induced toxicity is probably underestimated due to its latency and confounding factors like chemotherapy. A search of the literature for radiation induced renal toxicity was performed. Most toxicities occur around 18 months. Renal mobility is significant in terms of dosimetric consequences, in particular in the young child. In case of total body irradiation, the dose responsible for a 5% risk of toxicities is around 16 Gy in 2 Gy fractions over 2 weeks. For partial renal irradiation, the volume receiving 20 Gy should be below 32% of the total renal volume. Compensatory mechanisms remain po... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5422967 Wed, 16 Nov 2011 05:00:00 +0100 5422967 http://www.medworm.com/index.php?rid=5422968&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22082610%26dopt%3DAbstract Authors: Amet S, Deray G Abstract Cancer patients frequently undergo imaging examinations to diagnosis but also to evaluate their responses to treatment. These patients are also at high risk of kidney impairment before considering the possible nephrotoxicity of their chemotherapy. In this context, it is overriding to know contrast agents induced risks and what are the good practices to avoid them. Renal function evaluation takes a major part in there. The X-ray radiology using iodinated contrast agent (ICA) exposes patients to acute renal failure. This induced nephropathy is prevented by adequate hydration prior to injection when the glomerular filtration rate (GFR) of the patient is less than 60 ml/min/1.73 m(2). For hardly nephrotoxic, gadolinium-based contrast agents (GBCA) ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5422968 Tue, 15 Nov 2011 05:00:00 +0100 5422968 http://www.medworm.com/index.php?rid=5381809&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22049384%26dopt%3DAbstract Authors: Pourquier P, Lansiaux A Abstract Nuclear topoisomerase I (Top1) is involved in the relaxation of DNA supercoiling and plays a pivotal role in the coordination of essential DNA processes such as transcription, replication, DNA recombination and DNA damage signalling. For all these reasons, Top1 has been an attractive target for the development of anticancer drugs, which poison Top1 by trapping the enzyme on its DNA cleavage sites, which results in irreversible DNA lesions that are responsible for their cytotoxicity. They derive from the natural compound camptothecin and two derivatives are approved in the clinic, topotecan and irinotecan; other compounds such as indolocarbazoles and indenoisoquinolines are in development. However, the efficacy of these drugs is often limite... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5381809 Sat, 29 Oct 2011 04:00:00 +0100 5381809 http://www.medworm.com/index.php?rid=5381808&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22049385%26dopt%3DAbstract We present in this paper, for the three classes of antimetabolites, both ancient and recent molecules as well as molecules still in clinical trials, without exhaustivity. PMID: 22049385 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5381808 Sat, 29 Oct 2011 04:00:00 +0100 5381808 http://www.medworm.com/index.php?rid=5381815&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023787%26dopt%3DAbstract Authors: Robert J Abstract Membrane receptors with tyrosine kinase activity and cytoplasmic tyrosine kinases have emerged as important potential targets in oncology. Starting from basic structures such as anilino-quinazoline, numerous compounds have been synthesised, with the help of tyrosine kinase crystallography, which has allowed to optimise protein-ligand interactions. The catalytic domains of all kinases present similar three-dimensional structures, which explains that it may be difficult to identify molecules having a high specificity for a given tyrosine kinase. Some tyrosine kinase inhibitors are relatively specific for epidermal growth factor receptor (EGFR) such as géfitinib and erlotinib; other are mainly active against platelet-derived growth factor receptor (PDGFR) a... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5381815 Tue, 25 Oct 2011 04:00:00 +0100 5381815 http://www.medworm.com/index.php?rid=5381814&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023796%26dopt%3DAbstract Authors: Vrignaud P Abstract For oncology research, the tumor model selection is driven by the study objectives. Due to the cancer heterogeneity, different tumor models will be needed according to the development stages: target validation, proof of concept of target inhibition by a lead compound (small molecules or biotherapeutics), or candidate selection for further clinical development. In most of the cases, subcutaneous implantations of murine or human tumors are the best tools to address the preclinical questions helping to prepare the clinical development. Nevertheless, the development of more complex tumor models is also requested to answer more specific preclinical questions: either using surgical procedures to graft the tumor within a specific organ for evaluating specific ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5381814 Tue, 25 Oct 2011 04:00:00 +0100 5381814 http://www.medworm.com/index.php?rid=5381813&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023806%26dopt%3DAbstract Authors: Lansiaux A, Pourquier P Abstract Human nuclear topoisomerases II (Top2) are involved in the relaxation of DNA supercoiling during transcription and replication but also play a pivotal role in the segregation of newly replicated chromosomes and in chromatin remodelling. Top2 have been used as targets for the development of anticancer drugs. These inhibitors include anthracyclines (doxorubcin, daunorubicin, epirubicin) and epipodophyllotoxins (etoposide), which are widely used in the clinic. These drugs poison Top2 by trapping the enzyme on its DNA cleavage sites, which results in irreversible double-strand breaks that are responsible for cell death. They also include Top2 catalytic inhibitors such as bisdioxopiperazines (ICRF-187 and merbarone), which inhibit Top2 binding t... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5381813 Tue, 25 Oct 2011 04:00:00 +0100 5381813 http://www.medworm.com/index.php?rid=5381816&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22023745%26dopt%3DAbstract Authors: Dumontet C Abstract Microtubules are dynamic filamentous cytoskeletal proteins that are an important therapeutic target in patients with tumors. Microtubule binding agents have been part of the pharmacopoeia of cancer for decades, and until the advent of targeted therapy microtubules represented the only alternative to DNA as a therapeutic target in cancer. There are currently a variety of available vinca alkaloids and taxanes and other agents, such as ixabepilone and eribulin, have also been approved. Maytansinoids have been used for the production of immunoconjugates, monoclonal antibodies covalently bound to antimitotic molecules. The screening of a variety of botanical species and marine organisms continues to yield promising new antitubulin agents with novel propertie... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5381816 Mon, 24 Oct 2011 04:00:00 +0100 5381816 http://www.medworm.com/index.php?rid=5381812&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22024542%26dopt%3DAbstract Authors: Chatelut E Abstract Platinum compounds represent a pharmacological class, essential for the treatment of some cancer diseases. The three molecules, cisplatin, carboplatin, and oxaliplatin, share some physiochemical and pharmacological properties, in particular the ability to form DNA adducts. However, oxaliplatin presents some mechanisms of resistance different to those of cisplatin and carboplatin. Carboplatin may be considered as an analogue of cisplatin, but its pharmacokinetic properties, side effects, and intrinsic activity are significantly different from those of cisplatin, then the choice of one of these two compounds may be done rationally in function of the patients' characteristics. The cellular mechanisms involved in these differences are described in this gene... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5381812 Mon, 24 Oct 2011 04:00:00 +0100 5381812 http://www.medworm.com/index.php?rid=5381811&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22024557%26dopt%3DAbstract Authors: Chatelut E Abstract The interindividual variability in pharmacokinetics represents one of the factors involved in difference of both efficacy and toxicity of anticancer drugs prescribed to patients with the same cancer disease. The causes of pharmacokinetic interindividual variability are themselves divers. The impaired organic function corresponding either to liver or kidneys represents the major cause since any impaired function is systematically responsible of pharmacokinetic modifications, and due to the amplitude of these modifications. In this article, the clinically relevant pharmacokinetic parameters are shown. The methodologies used to study the pharmacokinetic variability due to impaired organic functions and to control them are detailed. PMID: 22024557 [PubM... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5381811 Mon, 24 Oct 2011 04:00:00 +0100 5381811 http://www.medworm.com/index.php?rid=5381810&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22024604%26dopt%3DAbstract Authors: Dubernet C Abstract The concept of drug targeting has resulted in a considerable variety of tools within nanotechnology, whose potentials in the special field of cancer are very interesting. There is a strong link between the structure and the surface of the vector on the one hand, and the biological target thus accessible on the other hand, as illustrated a number of typical examples. Parallel developments were made in the fields of therapy and diagnosis, stage by stage. The challenges now live in the combination of approaches widely reported under the terminology of "theranostics". PMID: 22024604 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5381810 Mon, 24 Oct 2011 04:00:00 +0100 5381810 http://www.medworm.com/index.php?rid=5381819&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22020743%26dopt%3DAbstract Authors: de Cremoux P Abstract The nuclear estrogen receptors (ER) are the major targets for endocrine treatment of hormone-dependent breast cancers. Hormone therapy blocked endogenous estrogen activation of ER, either by competitive inhibition of endogenous estrogens (selective estrogen receptor modulators - SERM or selective estrogen receptor down regulators - SERD) or by inhibition of estrogen synthesis (aromatase inhibitors) from adrenal androgens in post-menopausal women. The efficacy of these treatments has been shown on large series of breast cancer patients. However de novo or acquired resistance to treatment occurs. The better knowledge of the mechanism of action of such treatment may help to better understand them, and also for the determinism of adverse side effects of... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5381819 Thu, 20 Oct 2011 04:00:00 +0100 5381819 http://www.medworm.com/index.php?rid=5381818&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22020767%26dopt%3DAbstract Authors: Diallo A, Prigent C Abstract Cell cycle progression corresponds to a series of events, which succeed one another to end in the division of a mother cell to give two daughter cells. The processes that allow the cell to divide are very precisely controlled by a multitude of enzymatic reactions among which protein phosphorylation, carried out by protein kinases, plays a key role. Serine/threonine kinases are enzymes that catalyse the transfer of a phosphate from ATP to a protein substrate, more precisely on a serine or threonine amino acid residue. Three important families of serine/threonine kinases are involved in the regulation of cell cycle progression, the cyclin dependent kinase (CDK) the polo-like kinase (PLK) and those of the Aurora family. The cancer is described as ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5381818 Thu, 20 Oct 2011 04:00:00 +0100 5381818 http://www.medworm.com/index.php?rid=5381817&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22020797%26dopt%3DAbstract Authors: Pourquier P Abstract With the approval of mechlorethamine by the FDA in 1949 for the treatment of hematologic malignancies, alkylating agents are the oldest class of anticancer agents. Even though their clinical use is far beyond the use of new targeted therapies, they still occupy a major place in specific indications and sometimes represent the unique option for the treatment of refractory diseases. Here, we are reviewing the major classes of alkylating agents and their mechanism of action, with a particular emphasis for the new generations of alkylating agents. As for most of the chemotherapeutic agents used in the clinic, these compounds are derived from natural sources. With a complex but original mechanism of action, they represent new interesting alternatives for th... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5381817 Thu, 20 Oct 2011 04:00:00 +0100 5381817 http://www.medworm.com/index.php?rid=5330759&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22001702%26dopt%3DAbstract This study shows the importance of setting up an optimal unit of preparations according to its activity and highlights the high cost's variation in relation to the activity of the unit. PMID: 22001702 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5330759 Fri, 14 Oct 2011 04:00:00 +0100 5330759 http://www.medworm.com/index.php?rid=5330758&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22001771%26dopt%3DAbstract This article reviews the main dermatologic adverse events induced by these targeted anticancer therapies with a partial or exclusive antiangiogenic activity: sorafenib, sunitinib, pazopanib, vandetanib, everolimus, temsirolimus or bevacizumab. PMID: 22001771 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5330758 Fri, 14 Oct 2011 04:00:00 +0100 5330758 http://www.medworm.com/index.php?rid=5330757&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22001823%26dopt%3DAbstract Authors: Sujol G, Docquier A, Boulahtouf A, Castet-Nicolas A, Cavaillès V Abstract Vitamin B6 is well-known for its role as a cofactor in many enzymatic reactions and recently, several epidemiological studies have highlighted the importance of this vitamin as a protective agent against various cancers: elevated vitamin B6 plasma levels were associated with a lower risk of colorectal cancer development, for example. In vivo studies have shown that vitamin B6 decreased cell proliferation and enhanced the immune response. At the cellular level, antioxidant, pro-apoptotic and anti-angiogenic effects have been identified. At the molecular level, vitamin B6 is able to inhibit the transactivation potential of various nuclear receptors. Interestingly, a recent paper has described the... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5330757 Fri, 14 Oct 2011 04:00:00 +0100 5330757 http://www.medworm.com/index.php?rid=5330756&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D22001860%26dopt%3DAbstract Authors: Teghom C, Gachet J, Scotté F, Elaidi R, Oudard S Abstract In Europe, renal tumours are 7th in frequency of men cancers. They are rare tumours in 10 to 15% of cases. Collecting ducts carcinomas or Bellini tumours, described for the first time in 1949, are a distinct clinical and pathological entity. They represented 1% of epithelial cancers. Nephrectomy is the treatment of localised cancer. Because of lack of recommendations, usually in clinical practice, treatment is similar to urothelial carcinomas treatments (gemcitabine plus platinium). A 72% of response rate of urothelial carcinoma to association of bevacizumab with platinium and gemcitabine 1st line chemotherapy in metastatic setting was reported. More, cases of responses of metastatic Bellini cancers to antiangiogen... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5330756 Fri, 14 Oct 2011 04:00:00 +0100 5330756 http://www.medworm.com/index.php?rid=5330760&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21982780%26dopt%3DAbstract Authors: Fouquereau J, Laval G, Labarère J Abstract To assess the effectiveness of a standardized form in altering family physicians knowledge regarding supportive care delivered to their patients. We conducted an uncontrolled before and after study involving 42 cancer patients who were provided with supportive care at hospital. During the intervention study period, a standardized form was sent to their family physician within 1 week of discharge. The use of the standardized form was associated with an increase in the percentages of correct answers regarding consultations with psychologists (95% versus 19%, P < 0.001), social workers (95% versus 14%, P < 0.001), nutritionists (86% versus 9%, P < 0.001), and palliative care physicians (90% vers... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5330760 Mon, 10 Oct 2011 04:00:00 +0100 5330760 http://www.medworm.com/index.php?rid=5282133&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21700547%26dopt%3DAbstract Authors: Lheureux S, Le Moulec S Abstract Apoptosis is a programmed cellular death, a fast process (between four and six hours) in answer to a cellular stress. It involves a sequence of genetically determined intracellular events, allowing the inhibition of the main functions of the cell and its elimination by phagocytosis. The apoptosis inactivation is implied in tumours carcinogenesis. Although the tumour physiopathology implies a defect in activation-induced cell death, the treatment is designed to kill the transformed cells. The aim of this review is to describe the apoptotic mechanisms and to explain the interest of new therapeutic tools targeting apoptosis. Apoptosis is an orderly and synchronized process, regulated by two different pathways, the intrinsic way (mitochondrial)... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5282133 Sat, 01 Oct 2011 04:00:00 +0100 5282133 http://www.medworm.com/index.php?rid=5282132&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21715253%26dopt%3DAbstract Authors: Mansi L, Viel E, Curtit E, Medioni J, Le Tourneau C Abstract RAS proteins are among the first proteins to demonstrate a crucial implication in the cell cycle regulation. The RAS signalling pathway plays a key role in the regulation of cell cycle through the activation of numerous downstream pathways including the RAF/MEK/ERK, PI3K/AKT/mTOR, RAL and PKC pathways. These pathways are involved in gene transcription, regulation of cell survival and angiogenesis. As the RAS signalling pathway was shown to be altered in several cancers, molecularly targeted agents that trigger various components of this pathway have been evaluated in clinical practice. This paper first reviews the regulation processes of the RAS protein in cancer, as well as RAS downstream main signalling pathway... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5282132 Sat, 01 Oct 2011 04:00:00 +0100 5282132 http://www.medworm.com/index.php?rid=5282131&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21940239%26dopt%3DAbstract Authors: Faller E, Tunon de Lara C, Fournier M, Brouste V, Mathoulin-Pélissier S, Bussières E, De Mascarel I, Macgrogan G Abstract Intraoperative examination of sentinel lymph nodes (SLN) in breast cancer can avoid a new surgical procedure in case of positive SLN, but its value, efficacy and the methods used are still controversial. The aim of our study was to evaluate the imprint cytology intraoperative method of SLN analysis performed at our institution. We did a retrospective study of the sentinel lymph node procedures performed during a period of 24 months on cT1N0 unifocal breast cancers. Intraoperative procedure was mainly by imprint cytology (touch prep). A SLN procedure was performed on 187 women with 360 SLN. Two hundred and seventy-seven SLN among 156 women were anal... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5282131 Sat, 01 Oct 2011 04:00:00 +0100 5282131 http://www.medworm.com/index.php?rid=5247734&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21926034%26dopt%3DAbstract Authors: Asmane I, Kurtz JE, Bajard A, Guastalla JP, Meeus P, Tredan O, Labidi Galy I, Moullet I, Ardisson P, Vincent L, Coeffic D, Dufresne A, Bergerat JP, Ray-Coquard I Abstract As vascular endothelial growth factor (VEGF) is expressed in ovarian cancer, we assessed the efficacy and safety of bevacizumab (a monoclonal antibody targeting VEGF) plus microtubule targeting agents for heavily pre-treated ovarian carcinoma patients. We retrospectively reviewed 43 patients with recurrent epithelial ovarian carcinoma. Combined treatment included bevacizumab with paclitaxel in 32 (74%), docetaxel in 10 (23%), and vinorelbine in one (2.3%) patients, respectively. The median number of combined treatment was six cycles (range 1-29). On RECIST criteria, the objective response rate (ORR) was 4... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5247734 Thu, 15 Sep 2011 04:00:00 +0100 5247734 http://www.medworm.com/index.php?rid=5233415&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21914576%26dopt%3DAbstract Authors: Leblond P, Meignan S, Le Tinier F, Bethe U, Lansiaux A Abstract Last years saw the development of anti-angiogenic strategies in the treatment of cancers. Cilengitide (EMD121974; Merck KGaA, Darmstadt, Germany) is a new drug targeting αvβ3 and αvβ5 integrins thanks to a specific peptide called RGD sequence. Cilengitide acts in correlations between endothelial cells, tumor cells and extracellular matrix. The promising results obtained with Cilengitide in vitro, used alone or in combination with cytotoxic chemotherapy or ionizing radiations, could give many hopes especially for the treatment of cerebral tumors. Clinical trials are nowadays ongoing in this indication. The aim of this review is to take stock of the situation on the mechanisms of action of the integrin inhib... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5233415 Tue, 13 Sep 2011 04:00:00 +0100 5233415 http://www.medworm.com/index.php?rid=5233414&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21914577%26dopt%3DAbstract Authors: Joly F Abstract The perspectives of renal cell carcinoma (RCC) treatment have improved with the development of targeted molecular therapies against VEGFR/VEGF-mediated angiogenesis and mTOR. Antiangiogenic drugs, including bevacizumab (in association with IFN-α), sorafenib, sunitinib and pazopanib have demonstrated benefits for patients in terms of life expectancy, with progression free survival and overall survival exceeding 10 and 24 months, respectively. Long-term administration of these drugs, over several months or several years, requires the compliance of patients. Phase II/III studies on antiangiogenic-based therapy in RCC showed a high prevalence of fatigue (20 to 56%), whatever the drug assessed, but with the lowest rates observed with sorafenib or pazopanib. F... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5233414 Tue, 13 Sep 2011 04:00:00 +0100 5233414 http://www.medworm.com/index.php?rid=5233413&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21914578%26dopt%3DAbstract Authors: Motamed C, Bourgain JL Abstract As part of a quality assurance program, we assessed the trend of our analgesic consumption using our anesthesia database which include anesthesia and postanesthetic care records for all patients. In recent years, emphasis was made on anesthesia personnel to decrease postoperative opioid analgesic at the expense of non-opioid analgesics in order to decrease opioid related side effects. The following items were recorded: intraoperative opioid consumption, total morphine consumption, non-opioid analgesic consumption pain and sedation scores in the postoperative care unit (PACU). The database consisted of 57,967 patients for 9 consecutive years from 2002 to 2010, mean data exhaustivity was of 95%. Total morphine consumption per patient in the op... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5233413 Tue, 13 Sep 2011 04:00:00 +0100 5233413 http://www.medworm.com/index.php?rid=5233412&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21914579%26dopt%3DAbstract Authors: Poder TG, He J, Lemieux R Abstract The main objectives of this literature review are to determine if scalp cooling is efficient and safe, if there are side effects and if the patients' quality of life improves. In terms of effectiveness, scalp cooling seems to get good performance in its aim to prevent hair loss in patients receiving chemotherapy. The weighted average results of all identified studies indicate that this technology allows for 63.5% of patients to have a good preservation of their hair. In studies with a group of control, the weighted rates of good preservation of the hair are 50.6% with scalp cooling and 16.3% without. From the standpoint of safety technology, the main risk is that of scalp metastases. However, no study has successfully demonstrated a stati... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5233412 Tue, 13 Sep 2011 04:00:00 +0100 5233412 http://www.medworm.com/index.php?rid=5219577&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21908262%26dopt%3DAbstract Authors: Guillem P, Bolla M, Courby S, Descotes JL, Laramas M, Moro-Sibilot D Abstract Resulting medical decision from a multidisciplinary team (MDT) meeting has to be accurate regarding to various patient criteria and relevant specialists participation. The target is to optimize treatment or management options for patients taking into account patients' benefit. The aim of our study was to examine quality criteria of MDT meeting processes, implementation of the MDT decision, and the follow-up of national or regional clinical guidelines. The results lead us to discuss about care management in cancer. Ten various medical specialities of MDT meetings were studied. Relevant multidisciplinarity varied between MDT meetings specialities and was effective between 55 and 100%. Implementatio... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5219577 Thu, 08 Sep 2011 04:00:00 +0100 5219577 http://www.medworm.com/index.php?rid=5219576&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21908263%26dopt%3DAbstract This article presents a comprehensive analysis of the frequency of theses phenotypic changes altogether with new modalities to evaluate this phenotypic status. PMID: 21908263 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5219576 Thu, 08 Sep 2011 04:00:00 +0100 5219576 http://www.medworm.com/index.php?rid=5219575&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21908264%26dopt%3DAbstract Authors: Maurina T, Chaigneau L, Bazan F, Villanueva C, Thiery-Vuillemin A, Kalbacher E, Curtit E, Cals L, N'guyen T, Pivot X Abstract Breast cancer incidence remains the highest among gynaecologic neoplasms. Once they have achieved their treatments, patients should undergo careful follow-up. It aims at detecting early local recurrence or controlateral breast cancer. Based on large cohorts, clinical and radiological follow-up procedures come from guidelines realised by scientific organisations. We evaluated our regional practices in Franche-Comté and compared them to current guidelines. Patients with early breast cancer positive for hormonal receptors filled a questionnaire concerning their follow-up. It included patients treated from 1999 to 2005. When frequency of consultation i... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5219575 Thu, 08 Sep 2011 04:00:00 +0100 5219575 http://www.medworm.com/index.php?rid=5219578&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21896399%26dopt%3DAbstract Authors: Boulaamane L, Essaadi I, Lalya I, M'rabti H, Errihani H Abstract Cancer is an uncommon disease; its imaginary concept is very particularly on adolescent and young adults. It disturbs their lives on the whole. The purpose of this study is to describe the specific psychosocial effects of cancer on adolescent and young adults in Moroccan population in order to help physicians educate and counsel future young patients and their families. During the period from January to July 2009, patients aged between 15 and 30 years with histologically confirmed cancer, were prospectively interviewed by a questionnaire covering socio-epidemiological characteristics, repercussions of disease on physical, psychic, sexual and religious practices. The aim of this study is to determine the impac... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5219578 Tue, 06 Sep 2011 04:00:00 +0100 5219578 http://www.medworm.com/index.php?rid=5141950&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21835729%26dopt%3DAbstract Authors: Chabannon C, Calmels B, Habibi S, Mohty M, Imbert AM Abstract Mobilization is the biological phenomenon by which hematopoietic stem and progenitor cells (HSPC) transiently egress the bone marrow compartment and circulates in peripheral blood. The biological significance of this phenomenon is incompletely understood, although it is likely to be a component of physiological responses to various forms of stress, and needs for tissue repair. Some of the molecular actors that regulate HSPC mobilization have been unravelled. In addition, some of the inter-individual variability of this phenomenon can be ascribed to clinical as well as to biological parameters. The key role of the interaction between the chemokine SDF-1/CXCL12 and its receptor CXCR-4 has made it an attractive tar... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5141950 Wed, 10 Aug 2011 23:00:00 +0100 5141950 http://www.medworm.com/index.php?rid=5141949&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21835730%26dopt%3DAbstract Authors: Xhaard A, Hermet E, Bay JO, Peffault de Latour R Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice of hematologic malignancies. Acute graft versus host disease (GvHD) is common after HSCT and directly related to graft versus leukemia effect. Little progress has been done in the treatment of acute GvHD. The first line treatment is usually high-dose steroids for patients presenting grade II or more GvHD. However, 40% of those patients are resistant to this treatment. Several approaches using monoclonal antibodies against cytokines or other molecules involved in the physiopathology of GvHD have been used. The aim of this review is an updated overview of the mainly used monoclonal antibodies in the prophylaxis or treatment of GvHD (... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5141949 Wed, 10 Aug 2011 23:00:00 +0100 5141949 http://www.medworm.com/index.php?rid=5141948&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21835732%26dopt%3DAbstract Authors: Castagna L, Blaise D, Furst S Abstract Most of patients with hematological malignancies are elderly (more than 60 years). Allogeneic stem cell transplantation is an important and effective treatment for most of these diseases. However, the toxicity and the supposed frailty of elderly patients, have limited the applicability of allogeneic transplantation for these patients. Elderly patients are at high risk to develop life-threatening complications, if allogeneic transplantation is performed with myeloablative conditioning regimens and using bone marrow stem source. Since more than 10 years, reduced intensity conditioning regimen have been developed, allowing to overcome the age as contra-indication for allogeneic transplantation. On the other hand, it is the presence of ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5141948 Wed, 10 Aug 2011 23:00:00 +0100 5141948 http://www.medworm.com/index.php?rid=5141953&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21827980%26dopt%3DAbstract Authors: Wémeau M, Gauthier J, Leleu X, Yakoub-Agha I Abstract IMiDs belong to a new pharmalogical class, whose principal therapeutic agents are the thalidomide and the lenalidomide. They have immunomodulatory and antiangiogenic properties, as well as a direct effect on tumor cells. Thalidomide and lenalidomide were first approved for multiple myeloma, and in 5q-myelodysplastic syndrome for lenalidomide. Several studies have shown the efficacy of these drugs in others hematologic malignancies. A third component has been developed, the pomalidomide, which may be more effective in certain indications. Here we present an overview of IMiDs in hematology, including mechanisms of action and known significant side effects. PMID: 21827980 [PubMed - as supplied by publisher] (Source: B... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5141953 Tue, 09 Aug 2011 23:00:00 +0100 5141953 http://www.medworm.com/index.php?rid=5141951&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21827982%26dopt%3DAbstract Authors: Balsat M, Cornillon J Abstract Mammalian target of rapamycyin (mTOR) is a downstream serine/threonine kinase of the PI3K/AKT pathway that integrates signals from the microenvironment such as cytokines, growth factors, and nutriments to regulate multiple cellular processes, including mRNA translation, autophagy, metabolism, growth and survival. mTOR operates in two distinct multi-protein complexes: mTORC1 and mTORC2; sharing mTOR kinase as a common catalytic subunit, mTORC1 controls cell growth and mTORC2 modulates cell survival and drug resistance. mTOR signalling pathway has been found to be deregulated in many haematological malignancies, and has been designed as an attractive anti-tumor target. Thereby, mTOR inhibition with rapamycin (sirolimus) or its derivates (rapalo... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5141951 Tue, 09 Aug 2011 23:00:00 +0100 5141951 http://www.medworm.com/index.php?rid=5141952&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21827981%26dopt%3DAbstract Authors: Lemal R, Ravinet A, Moluçon-Chabrot C, Bay JO, Guièze R Abstract Histone deacetylases inhibitors (HDACi) represent a new epigenetic targeting therapy class, which is widely investigated in fundamental research and clinical trials. They are able to restore and increase tumor suppressor genes expression and to play an anti-tumoral activity through numerous targets, which are distributed all over the main differentiation, proliferation and survival cellular pathways. Their use in hematology led to vorinostat (SAHA) and romidepsin approval by FDA for the treatment of refractory cutaneous T-cell lymphomas. Preclinical and preliminary clinical results show a promising antineoplasic activity in most hematologic malignancies. This review will focus on the HDACi recent developmen... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5141952 Mon, 08 Aug 2011 23:00:00 +0100 5141952 http://www.medworm.com/index.php?rid=5141955&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21821481%26dopt%3DAbstract Authors: Massard C, Fléchon A, Fizazi K, Droz JP Abstract Germ cell tumors are cured by cisplatin-based chemotherapy and secondary surgery. Patients with initial poor response to chemotherapy and relapsed disease patients have poor prognosis. Among different therapeutic approaches high dose chemotherapy with hematopoietic stem cell support has been studied. Despite the existence of a number of phase II trials and several well-conducted phase III trials, this approach is neither a standard nor an option in the setting of first line and first salvage treatment. A randomized phase III trial has recently been initiated and patients with relapsed disease should be offered to participate in the trial. Several selected indications could be discussed in further lines of treatment. PMI... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5141955 Sun, 07 Aug 2011 23:00:00 +0100 5141955 http://www.medworm.com/index.php?rid=5141954&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21821482%26dopt%3DAbstract Authors: Itzykson R, Fenaux P Abstract Azacitidine has been approved in January 2009 in Europe in the treatment of higher-risk myelodysplastic syndromes (MDS). This represents the first time a drug is specifically labelled in MDS in Europe, and is a cornerstone in the development of hypomethylating agents 5-azacytidine (azacitidine) and 5-deoxyazacytidine (decitabine). Clinical trials of hypomethylating agents in MDS still raise a number of questions regarding the precise mode of action of these drugs, as well as the optimal sequencing of treatment in MDS. The positive results of these trials also open the field of epigenetic therapeutic strategies combining hypomethylating agents with other classes of drugs targeting epigenetic processes. PMID: 21821482 [PubMed - as supplied ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5141954 Sun, 07 Aug 2011 23:00:00 +0100 5141954 http://www.medworm.com/index.php?rid=5106089&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21816704%26dopt%3DAbstract Authors: Demarquet M, Labussière-Wallet H, Nicolas-Virelizier E, Nicolini FE Second-generation tyrosine kinase inhibitors (TKI 2) represent a recent important improvement in the treatment of Philadelphia positive leukemias. These agents are a suitable major option if resistance or significant imatinib intolerance occurs in chronic and accelerated phase CML. They are now introduced as first line therapy in chronic phase CML where they induce cytogenetic and molecular response rates never seen to date, which is promising for long-term survival. We propose here an analysis of the main current data available for the use of TKI 2 in CML. PMID: 21816704 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5106089 Thu, 04 Aug 2011 23:00:00 +0100 5106089 http://www.medworm.com/index.php?rid=5058822&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21752762%26dopt%3DAbstract Authors: Noël-Savina E, Quéré G, Gouva S, Robinet G, Descourt R Taking care of patients in oncology needs safety venous access, as percutaneous implantable port. These venous devices are sometimes responsible for serious adverse events. Infection and thrombosis are the two main complications that can occur early or be delayed. Clinical examination and especially, evaluation of the severity are very important keys to manage the patients. They both can lead to the ablation of the central venous device, which is an option to keep always in mind. However, whatever the clinical situation is, the oncologic context such as life expectancy and the need for a venous access is also a data to counterbalance. PMID: 21752762 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5058822 Mon, 11 Jul 2011 23:00:00 +0100 5058822 http://www.medworm.com/index.php?rid=5058823&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21742593%26dopt%3DAbstract Authors: Coutte L, Dreyer C, Sablin MP, Faivre S, Raymond E PI3K/AKT/mTOR pathway is an intracellular signalling pathway composed of different kinases. Many protein mutations are described in that pathway, and are responsible of dysregulation of cell growth, proliferation, survival and angiogenesis. Rapamycin is an antibiotic inhibiting mTOR. Different analogs of rapamycin are developped or being developped in antitumoral therapy, in which temsirolimus, everolimus and deforolimus, demonstrated antitumoral activity in renal cancer and mantle cell lymphoma, and many clinical trials are in progress in other tumors. In the future, predictive factors of response need to be identified; patient selection and associations with chemotherapy or with other targeted therapies should be explored. ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5058823 Thu, 07 Jul 2011 23:00:00 +0100 5058823 http://www.medworm.com/index.php?rid=5011311&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21737380%26dopt%3DAbstract Authors: Carassou P, Meijer L, Le Moulec S, Aoun J, Bengrine-Lefèvre L Protein phosphorylation is a fundamental post-translational modification. It regulates a large number of critical cellular processes (differentiation, division, proliferation, apoptosis). Cell division is a process including a series of phases by which a parent cell divides into two daughter cells. The cells enter these stages then progress within the cell division under an accurate control by many proteins. These proteins are activated by phosphorylation. Cyclin-dependent kinases are responsible for this phosphorylation and therefore represent potential therapeutic targets especially in oncology. PMID: 21737380 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=5011311 Wed, 06 Jul 2011 23:00:00 +0100 5011311 http://www.medworm.com/index.php?rid=4963069&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21690034%26dopt%3DAbstract Authors: Guichard JB, Garet M, Auberdiac P, Nourissat A, Roche F, Mélis A, Barthélémy JC, Chauvin F, Da Costa A, Chargari C, Merrouche Y, Jacquin JP, Collard O, Magné N <p>The purpose is to assess the physical activity of breast cancer patients using a questionnaire, the Population Physical Activity Questionnaire (POPAQ) and to compare the data with those from two female populations: one healthy population and one with a previous history of cardiovascular disease.</p><p>This prospective study included 104 consecutive breast cancer patients who were addressed at the radiation oncology department, Institut de cancérologie de la Loire from March to July 2010. A questionnaire using factorial method was used for assessment of physical activity.<... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963069 Sun, 19 Jun 2011 23:00:00 +0100 4963069 http://www.medworm.com/index.php?rid=4963068&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21690035%26dopt%3DAbstract Authors: Thariat J, Vedrine PO, Orbach D, Marcy PY, Badoual C, Butori C, Teissier N, Toussaint B, Castillo L Salivary gland tumors in children are rare: they correspond to 8-10% of head and neck pediatric tumors. Clinicians of all disciplines should be aware of this diagnosis in front of non-inflammatory mass of the parotid or in the territory of other salivary glands. In children, 50% of salivary gland tumors are malignant which contrasts with a 10-25% risk in adults. Epithelial tumors are the most common, mucoepidermoïd carcinomas of the parotid in particular. Surgery is the treatment of choice in epithelial tumors. Adjuvant radiotherapy may be indicated in case of unfavorable prognostic factors but must be balanced with the risk of radiation-induced growth defects and secondary can... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963068 Sun, 19 Jun 2011 23:00:00 +0100 4963068 http://www.medworm.com/index.php?rid=4963067&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21690036%26dopt%3DAbstract The objectives are to validate preclinical development and to acquire pharmacokinetic and pharmacodynamic data in order to better justify the scientific rational. In this article, we focus on phase 0 trials and their usefulness for the development of new drugs in oncology. We performed a literature review of questions related to phase 0 trials in articles published during 2006 to 2009. Thirty articles on phase 0 clinical trials have been published. The affected fields are oncology and pharmacology. Phase 0 clinical trials are discussed in the literature in terms of theoretical issues and from academic, pharmaceutical industry and patient point of views. If phase 0 clinical trials are a future prospect for drug development against cancer, the clinical applications of these trials need to be... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963067 Sun, 19 Jun 2011 23:00:00 +0100 4963067 http://www.medworm.com/index.php?rid=4963074&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21684834%26dopt%3DAbstract Authors: Rajpar S, Guittat L, Mergny JL The 2009 Nobel Prize for Physiology and Medicine was awarded to Elizabeth H. Blackburn, Carol W. Greider and Jack K. Szostak for their work on telomeres and telomerase. This prize acknowledges their pionneering discoveries on chromosomal extremities. Telomeres are the nucleoproteic complexes that may be found at the ends of linear chromosomes. They are essential for genomic stability and are involved in aging and tumorogenesis. PMID: 21684834 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963074 Thu, 16 Jun 2011 23:00:00 +0100 4963074 http://www.medworm.com/index.php?rid=4963073&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21684835%26dopt%3DAbstract Authors: Viel E, Curtit E, Mansi L, Vignot S EGFR may be considered as an old target, which can be inhibited both by monoclonal antibodies and tyrosine kinase inhibitors. Those molecular targeted strategies are now approved in a wild range of tumors: colorectal cancer, lung cancer, pancreatic cancer and head and neck cancer. This paper proposes to describe the development of anti-EGFR drugs, highlighting several strategies points. Predicting biomarkers have been extensively studied for these agents, sustaining the hallmarks of the development of molecular targeting drugs. PMID: 21684835 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963073 Thu, 16 Jun 2011 23:00:00 +0100 4963073 http://www.medworm.com/index.php?rid=4963072&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21684836%26dopt%3DAbstract Authors: Béchade D Screening high-risk individuals with imaging tests, such as endoscopic ultrasound and computed tomography, can lead to the detection and treatment of predominantly asymptomatic premalignant lesions. These pancreatic lesions consist of resectable, mostly branch-type non-invasive intraductal papillary mucinous neoplasms. Endoscopic ultrasound features of chronic pancreatitis are highly prevalent in high-risk individuals and these directly correlate with multifocal lobulocentric parenchymal atrophy due to pancreatic intraepithelial neoplasia. Long-term, multi-prospective studies are needed to determine if screening for early pancreatic adenocarcinoma and timely intervention will result in decreased pancreatic cancer incidence and mortality in high-risk individuals. ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963072 Thu, 16 Jun 2011 23:00:00 +0100 4963072 http://www.medworm.com/index.php?rid=4963071&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21684837%26dopt%3DAbstract Authors: Peugniez C, Fantoni S, Leroyer A, Skrzypczak J, Duprey M, Bonneterre J <p>An increasing number of patients is treated for breast cancer during their professional life. The aim of this study was to assess factors impacting return to work and time to return to work after treatment.</p><p>One thousand and sixty-seven patients less than 60 years of age, and surgically treated in our institution between January 1st, 2004 and December 31st, 2005 received a questionnaire with medical, sociodemographic and professional items. An answer was obtained in 586 cases. Two hundred and seventy-three patients were evaluable. All the clinical files of these patients were reviewed.</p><p>Overall, 79.8% of the patients returned to work af... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963071 Thu, 16 Jun 2011 23:00:00 +0100 4963071 http://www.medworm.com/index.php?rid=4963070&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21684838%26dopt%3DAbstract Authors: Marijon H, André F Fifteen percent of breast cancers overexpress Her2, a tyrosin-kinase receptor. Because of its prognosis and its incidence, several efforts have been done in the last years to better understand mechanisms of Her2 action. This led to the development of targeted therapies such as trastuzumab, monoclonal antibody directed against the Her2 extra-cellular domain. Trastuzumab provides significant clinical benefit in women with Her2-positive breast cancers. However, many women will either not respond or progress despite this treatment. The aim of this article is to summarize mechanisms of action of Her2 and of trastuzumab, and to better understand pathways activated in resistant tumors in order to identify ways to overcome them. PMID: 21684838 [PubMed - as supp... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963070 Thu, 16 Jun 2011 23:00:00 +0100 4963070 http://www.medworm.com/index.php?rid=4963076&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21669561%26dopt%3DAbstract Authors: Curtit E, Mansi L, Viel E, Dobi E, Chaigneau L, Nguyen T, Pivot X, Blay JY, Kalbacher E Scientific knowledge on gastrointestinal stromal tumors (GIST) has highly progressed over the last 10 years. The molecular bases of oncogenic transformation, KIT activating mutations, were identified in 1998 by Hirota et al. The product of KIT proto-oncogene, KIT protein, is a transmembrane receptor with tyrosine kinase activity. Tyrosine kinase inhibitors targeting these mutated activated kinases, namely imatinib and more recently sunitinib, nilotinib, masitinib or sorafenib, have deeply modified GIST prognosis. Molecular biology in GIST is now becoming a routine tool for treatment selection. In patients with advanced GIST, imatinib should be given until progression, and then, other tyros... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963076 Mon, 13 Jun 2011 23:00:00 +0100 4963076 http://www.medworm.com/index.php?rid=4963075&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21669563%26dopt%3DAbstract Authors: Levy A, Albiges-Sauvin L, Massard C, Soria JC, Deutsch E Genomic DNA is constantly under stress of endogenous and exogenous DNA damaging agents. Without proper care, the DNA damage causes an alteration of the genomic structure and can lead to cell death or the occurrence of mutations involved in tumorigenesis. During the process of evolution, organisms have acquired a series of response mechanisms and repair of DNA damage, thereby ensuring the maintenance of genome stability and faithful transmission of genetic information. The checkpoints are the major mechanisms by which a cell can respond to DNA damage, either by actively stopping the cell cycle or by induction of apoptosis. Two parallel signalling pathways, ATM and ATR respond to genotoxic stress by activating their downst... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963075 Mon, 13 Jun 2011 23:00:00 +0100 4963075 http://www.medworm.com/index.php?rid=4963079&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21659060%26dopt%3DAbstract This study is based on a questionnaire mailed to oncologists and pulmonologists in the region. Of 401 questionnaires, the response rate was 56%. Responses of 71 (20%) physicians practicing thoracic oncology are presented in this article. Eighty percent of physicians routinely screen occupational exposure in case of lung cancer. The oncologists are less likely than pulmonologists to screen it (50% vs. 12%, p = 0.0015). Sixty-one percent of practitioners do not routinely propose smoking cessation in stage IV. Sixty-nine percent of practitioners' reports obtain an appointment for PET-scanner within 15 days and 72% indicate that this equipment is located within 50 km of their place of practice. Sixty-two percent reports using a surgical team specialized in chest disease, which is located... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963079 Wed, 08 Jun 2011 23:00:00 +0100 4963079 http://www.medworm.com/index.php?rid=4963078&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21659062%26dopt%3DAbstract Authors: Melis A, Abboud K, Bourmaud A, Pacaut C, Bageacu S, Jacquin JP, Porcheron J, Merrouche Y, Magné N The peritoneal carcinomatosis of ovarian cancer led to the development of optimal cytoreduction surgery completed by hyperthermic intraperitoneal chemotherapy (HIPEC). The main goal of this study is to evaluate the feasibility, tolerance and efficacy of this technique in patients with ovarian cancer. A retrospective monocentric study has evaluated 43 patients with HIPEC procedures from 1995 to 2009. After a complete cytoreduction surgery, a HIPEC procedure with cisplatin is performed. Data on complications and survival parameters were collected. Prognostic factors were also analyzed. Post-surgery complications included one death due to a septic shock (2.3%) and six patients have... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963078 Wed, 08 Jun 2011 23:00:00 +0100 4963078 http://www.medworm.com/index.php?rid=4963077&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21659064%26dopt%3DAbstract Authors: Demiselle J, Lheureux S, Clarisse B, Sevin E, Joly F Antiangiogenic therapies have led to substantial progress in the management of kidney cancer, highly vascular tumor, and chemoresistant. These molecules have improved the prognosis of metastatic renal cancer. However, only a few isolated cases of complete response have been described and the evolution of these patients after treatment discontinuation remains unclear. From a series of patients treated for kidney cancer with antiangiogenic in first line, the purpose of this study was to identify patients in complete response in whom treatment had been interrupted. Complete response was defined according to RECIST criteria and data were collected retrospectively at the Centre François Baclesse - Caen. Five patients were iden... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4963077 Wed, 08 Jun 2011 23:00:00 +0100 4963077 http://www.medworm.com/index.php?rid=4920740&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21636352%26dopt%3DAbstract Authors: Thomas-Schoemann A, Alexandre J, Mongaret C, Azibi S, Dauphin A, Goldwasser F, Lemare F Use of complementary and alternative medicine (CAM) has been reported to be more and more frequent among cancer patients in USA. The aim of this study was to analyze among French cancer patients the prevalence of CAM use, focusing on antioxidants (AO) that could interfere with antitumor agents. Seventy-nine patients, treated by antitumor chemotherapy in oncology day care unit, participated to an interview (medium age = 60 years old). CAM use was reported by 42% of patients: mostly AO (24%) (selenium, green tea and vitamins ACE, more specifically), but also relaxation, acupuncture, hypnosis (19%) and homeopathy (15%). Among patients using CAM, 66% of them indicated that their physician... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4920740 Thu, 02 Jun 2011 23:00:00 +0100 4920740 http://www.medworm.com/index.php?rid=4920739&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21642049%26dopt%3DAbstract Authors: Malbranche C, Boulin M, Guiu B, Pernot C, Cercueil JP, Serge Aho L, Musat A, Bedenne L, Hillon P, Guignard MH, Fagnoni P Transarterial chemoembolization (TACE) is the standard treatment in patients with unresectable non-metastatic hepatocellular carcinoma (HCC). New drug eluting beads aim at improving efficacy of TACE in retaining as long as possible the anticancer drug within the tumor. Our monocentric study compares direct hospital medical costs, according to two different methods, for a first course of conventional TACE and for a first course of TACE using drug eluting beads in 30 patients with HCC. The average cost of a first course of conventional TACE valued by the analytic accounting system is 4 332 € versus 3 577 € for a first course of TACE using drug elutin... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4920739 Thu, 02 Jun 2011 23:00:00 +0100 4920739 http://www.medworm.com/index.php?rid=4920743&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21636344%26dopt%3DAbstract Authors: Rüegg C, Monnier Y, Kuonen F, Imaizumi N Radiotherapy is successfully used to treat cancer. Emerging evidence, however, indicates that recurrences after radiotherapy are associated with increased local invasion, metastatic spreading and poor prognosis. Radiation-induced modifications of the tumor microenvironment have been proposed to contribute to increased aggressive tumor behavior, an effect also referred to as tumor bed effect, but the putative mechanisms involved have remained largely elusive. We have recently demonstrated that irradiation of the prospective tumor stroma impairs de novo angiogenesis through sustained inhibition of proliferation, migration and sprouting of endothelial cells. Experimental tumors growing within a pre-irradiated field have reduced tumor angi... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4920743 Wed, 01 Jun 2011 23:00:00 +0100 4920743 http://www.medworm.com/index.php?rid=4920742&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21636345%26dopt%3DAbstract Authors: Debled M, Dalenc F, Mauriac L, Brain E New molecular classification is one of the cornerstones of current and future progress in research and patient care for breast carcinoma. For the larger hormone-receptor positive and Her-2 negative subgroup, which concerns 75% of the patients, endocrine therapy and chemotherapy may be considered. Looking toward new-targeted therapies, this paper reviews the current use of these two treatment modalities in adjuvant, neoadjuvant and metastatic settings of this disease. PMID: 21636345 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4920742 Wed, 01 Jun 2011 23:00:00 +0100 4920742 http://www.medworm.com/index.php?rid=4920741&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21636346%26dopt%3DAbstract Authors: Saâda E, Follana P, Peyrade F, Mari V, François E Malignant ascites are the cancer-associated accumulation of fluids in the peritoneal cavity. The neoplasms most frequently associated with ascites are ovarian, breast, colon, stomach and pancreas adenocarcinomas. Symptoms are abdominal distention, nausea, vomiting, anorexia, dyspnea and limbs oedemas. Several pathophysiological mechanisms might be implicated such as peritoneal carcinomatosis, lymphatic vessels' obstruction, portal hypertension or heart failure. Its diagnosis is most often performed in a context of already known neoplasia. Malignant ascites are associated with a pejorative evolution. Ascites which cannot be mobilized or show early recurrence and cannot be prevented by medical treatment are defined as refractor... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4920741 Wed, 01 Jun 2011 23:00:00 +0100 4920741 http://www.medworm.com/index.php?rid=4920745&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21622087%26dopt%3DAbstract Authors: Serrate C, Watson S, Vignot S The MET tyrosine-kinase receptor is implicated in embryonic development and tissue repair. It appears to be a key of tumour development since it drives cell migration and invasion and can induce the conversion from an epithelial to a mesenchymal phenotype. Aberrant signaling of the MET pathways is associated with an aggressive prognosis and a poor outcome. Preliminary clinical results of several MET inhibitors have been encouraging particularly in tumours in which MET was amplified or mutated. MET inhibition could be especially interesting in association with others drugs since activation of MET is a secondary event induced by hypoxia, inflammatory cytokines or HER inhibitors that could exacerbate the malignant properties of transformed cells. Mol... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4920745 Thu, 26 May 2011 23:00:00 +0100 4920745 http://www.medworm.com/index.php?rid=4920744&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21622089%26dopt%3DAbstract Authors: Hullo E, Cotta L, Rabeyrin M, Larroquet M, Plantaz D Carcinoid tumors are the most common endobronchial tumors in the pediatric population, and represent a rare cause of airway obstruction. Clinical manifestations are unspecific, and diagnosis is often delayed due to low clinical suspicion. These tumors are considered low-grade malignant neoplasms, and their evolution is usually favorable after surgery. However, local recurrence and/or metastases can occur with both typical and atypical carcinoid tumors, justifying the need of prompt diagnosis and long-term follow-up. PMID: 21622089 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4920744 Thu, 26 May 2011 23:00:00 +0100 4920744 http://www.medworm.com/index.php?rid=4920746&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21616749%26dopt%3DAbstract Authors: Sautès-Fridman C, Dieu-Nosjean MC, Damotte D, Fisson S, Fridman WH An increasing body of evidence underlines the prominent role of the immune microenvironment in cancer growth, invasion and metastasis. The local immune responses are specialized in the different organs. We will discuss the composition of the immune microenvironments and their role on tumor development in two cancers developing in opposite contexts: in the lung, which is at the interface of the outside world and in the eye, which is, an immunoprivileged site protected from it. We demonstrate that the immune system plays a major role in control of tumors, despite of these highly different tissue microenvironments. PMID: 21616749 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4920746 Wed, 25 May 2011 23:00:00 +0100 4920746 http://www.medworm.com/index.php?rid=4871413&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21609892%26dopt%3DAbstract Authors: Mazure NM, Brahimi-Horn MC, Pouysségur J Mitochondria originated from a distant ancestor: the α-proteobacteria. They evolved over millions of years in a symbiotic relationship in eukaryotic cells by favoring consumption of oxygen by the electron transport chain with production of ATP. Contemporary mitochondria still play a crucial role in providing energy but also in apoptosis. Because of this symbiotic relationship and their pivotal function, mitochondria undoubtedly participate in tumorigenesis. Genetic defects in mitochondrial DNA, blockade of oxidative phosphorylation and mitophagy in tumor cells modify the production of damaging reactive oxygen species and restrain apoptosis. As the environment of tumor cells becomes more and more hypoxic, the hypoxia-inducible factor (... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871413 Sun, 22 May 2011 23:00:00 +0100 4871413 http://www.medworm.com/index.php?rid=4871411&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21609894%26dopt%3DAbstract Authors: Soulié O, Vennin P, Reich M Confronted with a patient with a personality disorder, the oncologist must recognize it and adapt his treatment accordingly. Some pathological character types require interpersonal adjustments to ensure a good understanding of the cancer disease and also to obtain the best compliance with supportive care. Given the fact that specific pharmacological treatment does not exist, collaboration between oncologists and the psycho-oncology team is paramount. The interaction between the somatic disease and the psychiatric disorder demand collaboration among caregivers sharing explanations and recommendations. Clinical examples will illustrate each personality disorder and will focus on the several problems raised by the psychiatric disorder. Treatment princ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871411 Sun, 22 May 2011 23:00:00 +0100 4871411 http://www.medworm.com/index.php?rid=4871415&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21609890%26dopt%3DAbstract This article will review the clinical experience of using MIBG as targeted radiotherapy in neuroblastoma. The administration guidelines, toxicity, response and survival are discussed. Recent studies have evaluated combinations of (131)I-MIBG with myeloablative regimens such as chemotherapy agents with radiation sensitizing properties, or with biologic agents. Most of them report a response rate of 30-40% with (131)I-MIBG in patients with relapsed or refractory neuroblastoma. Due to this high response rates and low non-hematologic toxicity, (131)I-MIBG seems to be an interesting agent for incorporation into the upfront management of newly diagnosed patients with high-risk neuroblastoma. PMID: 21609890 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871415 Thu, 19 May 2011 23:00:00 +0100 4871415 http://www.medworm.com/index.php?rid=4871414&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21609891%26dopt%3DAbstract Authors: Normand C, Michon J, Janoueix-Lerosey I, Delattre O, Schleiermacher G Neuroblastoma, the most frequent solid extracranial tumor of childhood, is characterized by a wide variability of its clinical course. The most important clinical prognostic markers are stage and age at diagnosis, but these markers are insufficient to predict outcome reliably and to determine treatment intensity. Recent evidence indicates that neuroblastoma can be considered as a "genetic disease", firstly by the recent observation that certain alleles of specific genes significantly increase the relative risk to develop neuroblastoma, and the discovery of mutations in genes such as ALK or PHOX2B in rare familial cases. On the other hand, a large number of recurrent genetic somatic alterations have been desc... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871414 Thu, 19 May 2011 23:00:00 +0100 4871414 http://www.medworm.com/index.php?rid=4871412&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21609893%26dopt%3DAbstract Authors: Poirot C, Schubert B Gonadotoxic therapies during childhood may impair future fertility in adult life and fertility preservation techniques should be discussed before starting gonadotoxic therapies. In both sexes, fertility preservation often means immature gametes cryopreservation. For girls, ovarian tissue cryopreservation is the only existing option to preserve fertility in prepubertal girls at risk of premature ovarian failure. This promising approach involves the storage of a large number of follicles, which could subsequently be transplanted or cultured to obtain mature oocytes. The results of ovarian tissue cryopreservation in adults are encouraging. At least nine children have been born after orthotopic reimplantation of frozen-thawed ovarian cortex. None of these preg... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871412 Thu, 19 May 2011 23:00:00 +0100 4871412 http://www.medworm.com/index.php?rid=4871410&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21609895%26dopt%3DAbstract In conclusion, comparison of primary normal (HRE) to primary pathological cells (pTEC and RCC) highlights two major issues: (1) IL-15 is a major regulator of epithelial homeostasis; (2) "apparently normal" pTEC cells, could contribute to organize a generalized "pre-neoplastic" environment committed to favour tumour progression. PMID: 21609895 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871410 Thu, 19 May 2011 23:00:00 +0100 4871410 http://www.medworm.com/index.php?rid=4871409&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21609896%26dopt%3DAbstract Authors: Haie-Meder C, Martelli H, Dumas I, Mazeron R, Oberlin O Publications on brachytherapy in paediatric malignancies are scarce, limited to expert institutions. Techniques, brachytherapy modalities (low dose-rate, high dose-rate, pulsed dose-rate), doses and indications vary according to centres. The most frequent tumor sites treated with brachytherapy are gynaecological rhabdomyosarcomas, prostate/bladder rhabdomyosarcomas and soft-tissue sarcomas. Brachytherapy advantages are in relation with ballistic properties, allowing a very high dose to the target with normal tissue sparing. This review analyzes brachytherapy techniques and indications according to tumor sites, brachytherapy results and perspectives. This technique requires a muldisciplinary approach. PMID: 21609896 [P... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871409 Thu, 19 May 2011 23:00:00 +0100 4871409 http://www.medworm.com/index.php?rid=4871417&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21596652%26dopt%3DAbstract Authors: Leblond P, Geoerger B Progresses performed in pediatric oncology during the last 30 years allowed to obtain about 70 to 80% healing rates. These progresses are the result of the optimization of the cytotoxic chemotherapies protocols used at standard and high doses, as well as the improvement of the local treatment. Most of the new anticancer treatments currently in developmental stage are based on targeted therapies, acting against numerous tumor cell abnormalities, like growth factors et their receptors, cell proliferation-inducing factors, molecules involved in DNA repair, cell death inducers, tumor invasion and angiogenesis. They are widely used in adult patients since 10 years and they are being more and more employed in children with cancer. The aim of this article is t... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871417 Wed, 18 May 2011 23:00:00 +0100 4871417 http://www.medworm.com/index.php?rid=4871416&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21596653%26dopt%3DAbstract Authors: Leblond P, Delebarre M, Aubert S Adrenocortical carcinomas are rare in children and sometimes occur in patients with predisposing syndrome like Li-Fraumeni or Beckwith-Wiedemann syndromes. The diagnosis is often based on clinical, biological and radiological findings completed by histological examination. The gold standard of treatment remains radical surgery sometimes completed by a cytotoxic chemotherapy based on platinum-derived drugs, etoposide and doxorubicin, in association with mitotane in case of high risk of relapse. The role of radiation therapy is discussed because of the relatively frequent involvement of p53 mutations. The rarity of this type of disease and the poor prognosis of the locally advanced and metastatic forms must lead to the systematic registration of ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871416 Wed, 18 May 2011 23:00:00 +0100 4871416 http://www.medworm.com/index.php?rid=4871420&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21576045%26dopt%3DAbstract Authors: Paillard C, Lutz P, Michel G, Leverger G, Dalle JH, Demeocq F, Kanold J Better understanding of the antitumor effect of allogeneic transplant and the need to reduce the toxicity of the procedure, particularly in elderly patients have spurred the development of reduced-intensity conditioning regimens (RIC). These regimens allow fast engraftment with very low chemotherapy-induced toxicity. They are widely used in adults and there are numerous studies to demonstrate their feasibility and efficiency, but in pediatrics, the place of RIC remains to be determined. They can be proposed in two pediatric populations. First, solid tumors or hematological malignancies remaining unresponsive to the reference strategies according to best practices in pediatrics. Second, in children presenti... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871420 Mon, 16 May 2011 23:00:00 +0100 4871420 http://www.medworm.com/index.php?rid=4871419&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21576046%26dopt%3DAbstract Authors: Gauthier-Villars M, Stoppa-Lyonnet D Cancer predisposition syndromes affecting children are rare. One can estimate that only 10% of all childhood cancers are related to predisposition. The identification of these syndromes remains important for the care of an affected child and relatives. If most of the known cancer predisposition syndromes are linked to a dominant inheritance associated with a high risk of cancer, new syndromes associated with complex inheritance are being identified. Diagnosis of a childhood cancer associated with early-onset or multiple lesions, or a malformation syndrome, or a positive family history of cancer should raise an alarm of a cancer predisposition syndrome. PMID: 21576046 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871419 Mon, 16 May 2011 23:00:00 +0100 4871419 http://www.medworm.com/index.php?rid=4871418&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21576047%26dopt%3DAbstract Authors: Claude L, Todisco L, Leseur J, Laprie A, Alapetite C, Bernier V Despite the risk of long-term side effects, external radiation therapy remains a cornerstone of the treatment for many cancers in childhood, in particular for brain tumours and head and neck cancers. Conformal radiation has been the standard of care since several decades. However, new techniques, including stereotactic radiation, intensity-modulated radiation therapy, or protontherapy have proven many advantages in adults, and are more and more discussed in pediatric management due to a favourable cost/benefit rate in some situations. The aim of this article is to point out the potential indications as well as the limits of these new techniques in childhood. PMID: 21576047 [PubMed - as supplied by publisher] (... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871418 Mon, 16 May 2011 23:00:00 +0100 4871418 http://www.medworm.com/index.php?rid=4871421&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21576044%26dopt%3DAbstract This article sheds light on the personal experience throughout various departments of pediatric oncology and hematology. PMID: 21576044 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4871421 Sun, 15 May 2011 23:00:00 +0100 4871421 http://www.medworm.com/index.php?rid=4815711&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21543285%26dopt%3DAbstract Authors: Petithuguenin Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, Laurence V, Livartowski A, Mignot L, Dieras V <p>Among all solid tumors breast cancer is the most common cause of meningeal carcinomatosis (MC). The purpose of this study was to analyze clinical and biological responses as well as overall survival in MC patients (pts) of breast primary treated with intrathecal methotrexate (MTX).</p><p>Single-center retrospective series of MC pts treated between 2000 and 2007. Chemotherapy regimen was: MTX (15 mg/day; day1-5) and depomedrol (40 mg, day 1) plus leucoverin (12 mg IV or 25 mg PO; day 1-5). Treatment cycles were repeated every 2 weeks. The survival was analyzed according to the characteristics of the tumor considering clinic... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4815711 Wed, 04 May 2011 23:00:00 +0100 4815711 http://www.medworm.com/index.php?rid=4815714&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21540145%26dopt%3DAbstract Authors: Dutertre G, Pouit B Questions about both the place and the role of surgery on brain metastasis from breast cancer are arising more and more frequently in practice due to the increase of brain metastasis in patients suffering from a form of cancer recognized as one of the most recurrent cancers in adults but also one of the most sensitive to general treatments of the systemic disease. With improvements in anaesthesia, in surgical instruments, and in global care, neurosurgery has taken advantage of new techniques such as pre- and even per-operative imagery and also neuronavigation. These techniques enable radical and effective surgical intervention with a high level of safety for the patient, making neurosurgery perfectly competitive with other therapeutic modalities, particular... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4815714 Tue, 03 May 2011 23:00:00 +0100 4815714 http://www.medworm.com/index.php?rid=4815713&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21540147%26dopt%3DAbstract Authors: Gutierrez M, Lyazidi S, Brasseur L, Cvitkovic F, Le Scodan R Leptomeningeal metastases are very commonly associated with breast cancer. The prognosis is very poor in the short term with an overall median survival less than 6 months. Based on pragmatic and historical considerations intrathecal chemotherapy (IT) are considered to be the adequate treatment. However overall results are disappointing. Despite specific and symptomatic treatment, improvement in survival and quality of life remains very modest, highlighting the importance for ongoing research for developing new molecules or on improving the use a better use of those available today. The incidence of leptomeningeal metastases is particularly marked in cases of overexpression of HER2. The main hypothesis is there may be... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4815713 Tue, 03 May 2011 23:00:00 +0100 4815713 http://www.medworm.com/index.php?rid=4815712&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21540148%26dopt%3DAbstract Authors: Le Tourneau C The incidence of brain metastases is particularly high in HER2-overexpressing (HER2+) breast cancer. Several hypotheses have been raised trying to explain this peculiar phenomenon, including a better control of extra-cerebral metastases with HER2-targeting agents, but also the own effect of HER2+ tumor cells that may have a marked brain tropism. In this context, the development of prevention strategies is highly relevant. After a brief description of the natural history of HER2+ breast cancer, three different prevention strategies are discussed in this article, including a secondary prevention strategy by systematic screening of brain metastases, and two primary prevention strategies with prophylactic cerebral irradiation and the optimisation of the adjuvant trea... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4815712 Tue, 03 May 2011 23:00:00 +0100 4815712 http://www.medworm.com/index.php?rid=4815719&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21540137%26dopt%3DAbstract Authors: Kallel A, Bailon O, Carpentier AF Cancer patients frequently develop brain metastases. Symptomatic treatments are important to stabilize these patients before an oncological procedure (usually radiotherapy, sometimes surgery or chemotherapy) can be started. These symptomatic treatments mainly rely on steroids to reduce the peritumoral edema; anti-epileptic drugs for patients who previously had seizures, and low-molecular-weight heparin for patients at risk of thrombo-embolic events. PMID: 21540137 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4815719 Mon, 02 May 2011 23:00:00 +0100 4815719 http://www.medworm.com/index.php?rid=4815718&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21540138%26dopt%3DAbstract Authors: Le Scodan R, Massard C, Jouanneau L, Gutierrez M, Mouret-Fourme E Approximately 10 to 30% of patients with metastatic breast cancer will develop brain metastases (BM) during the disease course. Whole-brain radiation therapy (WBRT) is considered the standard treatment for most patients, particularly those with extensive intracranial disease, providing symptom relief and increasing median and overall survival. Despite WBRT, the prognosis for the general population of patients with BM remains poor, with a median survival time of approximately five months. Several studies have examined the relative contributions of patient characteristics to survival and have attempted to identify subgroups of patients with substantially different outcomes in order to tailor therapy and to influen... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4815718 Mon, 02 May 2011 23:00:00 +0100 4815718 http://www.medworm.com/index.php?rid=4815717&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21540139%26dopt%3DAbstract Authors: Gachet J, Giroux J, Girre V, Brain E, Kirova Y, Mignot L, Mazeron JJ, Dutertre G, Pouit B, Mosseri V, Falcou MC, Cottu PH Breast cancer is the second cause for brain metastases. Their incidence is rising, partly due to the therapeutic improvements which alter the natural history of breast cancer. Predictive factors for brain metastases have been identified: HER2 oncogene overexpression, lack of expression of hormone receptors, young age and triple negative status. Brain metastases prognosis remains poor with a median survival shorter than 1 year, except for solitary lesions treated by surgery or radiosurgery. We have analysed two series of data from Institut Curie (Paris and Saint-Cloud). In women younger than 65 years, with HER2 negative breast carcinoma, median survival was ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4815717 Mon, 02 May 2011 23:00:00 +0100 4815717 http://www.medworm.com/index.php?rid=4815716&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21540140%26dopt%3DAbstract Authors: Kirova YM, Chargari C, Mazeron JJ Whole brain radiotherapy remains standard in the management of breast cancer patients with brain metastases. It allows for symptomatic improvement and good local control in most patients. However, its results remain suboptimal in terms of both efficacy and toxicity. In highly selected patients, stereotactic radiotherapy demonstrated very good local control with low toxicity. With purpose of improving the efficacy/toxicity ratio, strategies of biomodulation of tumor radiosensitivity were recently developed. First results are promising and warrant further assessment. At the same time, new technologies and new irradiation modalities demonstrated their ability in providing high dosimetric homogeneity, delivering integrated radiation boosts, and av... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4815716 Mon, 02 May 2011 23:00:00 +0100 4815716 http://www.medworm.com/index.php?rid=4815715&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21540141%26dopt%3DAbstract Authors: Gerber S, Ollivier L, Ala-Eddine C, Neuenschwander S CNS involvement in breast cancer modifies the prognosis and the treatment of the disease. Imaging plays a leading role for the diagnosis, the pretherapeutic assessment and the follow-up. MRI is the most sensitive modality for the detection of infraclinic lesions, reported in about 15% of metastatic breast cancers. In addition to conventional MR study, diffusion MR, perfusion MR and spectroscopy have a diagnostic value with specificity of more than 95%; 3D study is required if neurosurgical resection or stereotactic radiosurgery is contemplated. The use of new drugs in clinical trials needs a precise and accurate follow up to assess their usefulness; appreciation of the response is based on the precise mesure of the number of... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4815715 Mon, 02 May 2011 23:00:00 +0100 4815715 http://www.medworm.com/index.php?rid=4815721&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21527365%26dopt%3DAbstract Authors: Riahi Idrissi H, Chargari C, Bollet MA, Le Scodan R, Olivier L, Dorval T, Marchand V, Cottu P, Dieras V, Campana F, Fourquet A, Kirova YM <p>We retrospectively assessed the use of trastuzumab concurrently with whole-brain radiotherapy (WBRT) for brain metastases.</p><p>From April 2001 to April 2007, 31 patients with brain metastases from HER2-positive breast cancer were referred for WBRT with concurrent trastuzumab. In most cases, concurrent WBRT delivered 30 Gy in 10 daily fractions. In six patients, other fractionations were chosen because of either poor performance status or patients' convenience.</p><p>At time of brain progression, median age was 55 years (range: 38 to 73 years) and all patients had a performance status of 0 to 2. Media... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4815721 Thu, 28 Apr 2011 23:00:00 +0100 4815721 http://www.medworm.com/index.php?rid=4815720&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21527366%26dopt%3DAbstract Authors: Diéras V, Pierga JY Brain metastases are prevalent in solid tumours and lymphomas. They are associated with poor survival. The brain is regarded as a sanctuary site for metastatic tumour cells where they exist partially protected from drugs by the blood brain barrier. Amongst the different molecular sub-types of breast cancer, HER2 positive tumours and triple negative tumours exhibit the highest incidence of brain metastasis. Specific strategies are needed to fight brain metastatic disease. Preclinical models for brain metastasis have been developed, yielding mechanistic molecular knowledge and new therapeutic approaches. PMID: 21527366 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4815720 Thu, 28 Apr 2011 23:00:00 +0100 4815720 http://www.medworm.com/index.php?rid=4710169&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21454154%26dopt%3DAbstract Authors: Foray N, Verrelle P To study the biological mechanisms of the repair of the radiation-induced DNA damage leads to two major medical applications: (1) the identification of the radiosensitive patients by using appropriate predictive assays in order to avoid toxicity due to radiation therapy and sometimes to chemotherapy; (2) the decrease of the radioresistance of tumour cells to obtain a better local control. To transpose fundamental biological knowledge from experimental in vitro clinic is delicate and sometimes too hasty, though necessary. In mechanistic terms, clinical features are once again a very rich and under-exploited approach to identify the molecular mechanisms of the DNA repair function. An exhaustive survey of the clinical cases of radiosensitivity with biological ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4710169 Wed, 30 Mar 2011 23:00:00 +0100 4710169 http://www.medworm.com/index.php?rid=4655213&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21414891%26dopt%3DAbstract We report five cases of metastatic cutaneous hematomas of melanoma. This clinical presentation doesn't seem to be so rare. This clinical variant should be known from oncologists in order to perform a biopsy looking for a metastatic cutaneous involvement from melanoma. PMID: 21414891 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4655213 Tue, 22 Mar 2011 00:00:00 +0100 4655213 http://www.medworm.com/index.php?rid=4655211&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21427028%26dopt%3DAbstract Authors: Guièze R, Ravinet A, Hermet E, Maliki Y, de Botton S, Bay JO The survival improvement of patients treated with chemotherapy or radiotherapy for malignancies are increasing therapy-related acute myeloid leukemia (t-AML). It was thought to be the direct consequence of genetic events induced by such treatments. We here review the mechanisms of specific chemotherapy-related DNA damage inducing the chromosomal or genomic abnormalities characteristic of t-AML. We also focus on how such aberrations could initiate or participate to leukemogenesis. However, only a part of patients exposed to cytotoxic therapy is developing t-AML, suggesting that some genetic predisposition may be involved such as polymorphisms in genes related to DNA repair. PMID: 21427028 [PubMed - as supplied by... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4655211 Tue, 22 Mar 2011 00:00:00 +0100 4655211 http://www.medworm.com/index.php?rid=4655212&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21414892%26dopt%3DAbstract Authors: Pourquier P, Robert J DNA repair is implemented through a large variety of mechanisms, each of them being adapted to a specific type of lesion: direct repair, mismatch repair for the errors occurring during the replication process, base-excision repair, nucleotide-excision repair, double-strand breaks DNA repair by homologous or non-homologous recombination. Each of these mechanisms involves numerous proteins associated as supramolecular functional complexes. Some anticancer drugs are able to generate DNA lesions which may overflow the repair mechanisms. The impossibility to repair DNA damage usually leads to cell death, but alterations of repair mechanisms may favour genetic instability and hence contribute to oncogenesis. PMID: 21414892 [PubMed - as supplied by publisher... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4655212 Wed, 16 Mar 2011 00:00:00 +0100 4655212 http://www.medworm.com/index.php?rid=4593068&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21382771%26dopt%3DAbstract Authors: Leblond D, Brédart A, Dolbeault S, De Pauw A, Stoppa Lyonnet D, Flahault C, Sultan S Recent advances in oncogenetics have enabled the development of tests for predisposition to breast and ovarian cancers. Where no mutation has been identified in the <i>BRCA1</i> or <i>2</i> genes, the proband (first person tested in a family with a genetic risk) can receive an uncertain outcome: negative inconclusive or identification of a variant of unknown clinical significance. From the demonstration of such outcomes, their psychological impact has been studied among women concerned. The purpose of this article is to summarize the results of studies about the impact of delivering an uncertain<i> BRCA1/2</i> genetic result on emotional (general or cancer ... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4593068 Fri, 25 Feb 2011 00:00:00 +0100 4593068 http://www.medworm.com/index.php?rid=4593067&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21382773%26dopt%3DAbstract Authors: Marie-Cardine A, Berrebi D, Orbach D The paediatric rare tumours group from the <i>Société française des cancers de l'enfant </i>makes syntheses and guidelines for diagnosis and treatment for localized paediatric inflammatory myofibroblastic tumours according to international articles. All ages are concerning. Localizations are ubiquitous, more frequently in the superior and inferior airway. Histology showed a majority of fusiform cells, corresponding to myofibroblastic cells and an inflammatory infiltrate. Inflammatory myofibroblastic tumour diagnosis should only be confirmed in the absence of sarcoma molecular markers. Distinction between inflammatory myofibroblastic tumour and sarcoma is essential due to the different care. The curative treatment of inflammat... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4593067 Fri, 25 Feb 2011 00:00:00 +0100 4593067 http://www.medworm.com/index.php?rid=4593066&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21382791%26dopt%3DAbstract The objective of this study is to describe the QoL and psychological state's evolution in patients treated by conservative treatment for CM. Sixty-nine patients treated for CM by conservative treatment (proton beam irradiation or iodine plaques). QoL (EORTC-QLQ-C30 + QLQ-OPT-30), anxiety and depression (HADS, STAI-B-trait). Prospective study comprising four evaluations T0: before the beginning of the treatment, T1: one month, T2: six month, T3: one year after the treatment. The preliminary results of the first two evaluations showed that the level of the QoL remained relatively good and stable with an exception for the social functioning, which decreased after the treatment. More than half of the patients had a moderated rate of anxiety before the beginning of the treatment, which decr... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4593066 Fri, 25 Feb 2011 00:00:00 +0100 4593066 http://www.medworm.com/index.php?rid=4593065&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21382793%26dopt%3DAbstract In conclusion, small animal imaging with μscan is a non-invasive, reliable, and reproducible method for preclinical evaluation of antitumor agents. PMID: 21382793 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4593065 Fri, 25 Feb 2011 00:00:00 +0100 4593065 http://www.medworm.com/index.php?rid=4593064&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21382794%26dopt%3DAbstract Authors: Bonneau C, Bricou A, Barranger E Lymph node status is a major prognostic element in endometrial cancer and affects the choice of adjuvant therapy. The sentinel lymph node (SLN) procedure is proposed as an alternative to lymphadenectomy. This review aims to assess its feasibility. To this end, 19 studies have been analysed. It appears that double detection (colorimetric and isotopic) is better than single detection, independent of injection site. Hysteroscopic injection is technically more difficult, yet can be done near the tumoral lesion. The cervical site does not accurately reflect the lymphatic drainage of the uterine body but is easier to access. SLN detection rate is notably identical between these two injections sites. Lomboaortic detection rate is lower for cervical in... Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4593064 Fri, 25 Feb 2011 00:00:00 +0100 4593064 http://www.medworm.com/index.php?rid=4593063&cid=s_37643_6_f&fid=37643&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Fquery.fcgi%3Ftmpl%3DNoSidebarfile%26db%3DPubMed%26cmd%3DRetrieve%26list_uids%3D21382795%26dopt%3DAbstract Authors: Hau Desbat NH, Auberdiac P, Chargari C, Merrouche Y, Deutsch E, Schmitt T, de Laroche G, Magné N Since the 1990, chemoradiation has become the standard treatment for locally advanced anal cancer. Recent progress in molecular biology and the growing number of elderly patients invite the clinicians to personalize the multimodal therapy strategy. However, data about anal cancer and elderly patients or targeted therapy are extremely sparse. Indeed, national or international guidelines don't mention these two subjects. The purpose of this article is to make the state of art of the management of anal cancer and its interferences with geriatrics and molecular targeted therapy. PMID: 21382795 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer) Bulletin du Cancer journals http://www.medworm.com/rss/comments.php?id=4593063 Fri, 25 Feb 2011 00:00:00 +0100 4593063